,ticker,content
0,ZTS,zoetis zts plunge month low wednesday top wall street first quarter expectation note competition hurt product profit guidance lag penny early trading stock market today zoetis share gap crash day move average earlier fall much same time drug stock collectively lose more quarter zoetis report adjust income cent share rise ahead view analyst poll zack investment research nickel sale grow beat analyst view revenue be sale product pet rise drive growth dermatology new product growth be partially offset lower sale certain line product due expect competition zoetis say news release get newsletter deliver inbox more info product service privacy policy term usesale livestock product advanced lead cattle poultry well return growth swine business unfavorable condition dairy persist include decline producer profitability due low milk price internationally sale grow sale pet product grow help dermatology oral parasiticide vaccine china livestock product sale advanced strong demand poultry cattle globe livestock product account sale pet product grow contract manufacturing plummet year zoetis guide adjust profit share sale midpoint adjust profit miss consensus penny midpoint sale guidance narrowly beat analyst view sale related build long term profit stock take many gain look next nvidia start simple routinewhat be inflation do matter fed
1,ZTS,pharmaceutical company zoetis zts plan acquire abaxis abax nearly propel abaxis stock break morning trade wednesday deal value abaxis share cash abaxis make chemical analyzer used human veterinary patient zoetis pharmaceutical company make drug use animal health acquisition be expect close end year raymond james analyst john ransom call price tag rich represent premium abaxis stock prior close price only premium high see january abaxis shareholder price be reasonable firm be unlikely get bid say note view price somewhat rich relative asset have not perform exceedingly well late core chemistry growth somewhat question mind investor say get newsletter deliver inbox more info product service privacy policy term investor reward abaxis stock stock market today abaxis share pop close have be consolidate buy point be stock buy zone tuesday zoetis share dip fraction zoetis see deal boost animal diagnostic exposure firm estimate market be value north compound annual growth rate past year zoetis expect segment continue outgrow overall animal health market together bring more veterinarian customer broader range product fit comprehensive solution innovation prediction early detection disease animal prevention treatment zoetis chief executive juan alaix say written statement raymond james ransom say deal make sense zoetis be already country save abaxis time expense slow build global infrastructure recently abaxis expand europe latin america asia pacific zoetis be logical very interested buyer ransom say buy scandinavian micro biodevice expand pipeline veterinary diagnostic smaller firm make lab chip diagnostic acquisition scandinavian micro biodevice abaxis suggest zoetis have desire more meaningfully enter field exist rapid assay product line say abaxis chief executive clint severson see prime opportunity grow business part zoetis fiscal year end march abaxis generate sale vs last year year sale be diagnostic service veterinary market zoetis have global presence direct veterinary customer relationship deliver greater value more customer world accelerate growth international operation severson say prepared statement related much money do need start investing long term retirement investing strategy etfslook best stock buy watch start here
2,ZTS,welcome move astrazeneca azn see relative strength rating improve thursday look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily identify market leadership worst best score rating show stock price movement last week hold other stock database year market history show stock go make biggest gain typically have rs rating least begin biggest price move see astrazeneca continue rebound hit benchmark see ibd help make more money break earlier be now trading approximately prior entry cup handle scenario stock break then fall more entry price consider fail happen best new pattern form also keep mind most recent consolidation be later stage base make riskier establish new position add share exist earning growth picked last quarter sale fall look next report apr company earn rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz shire shpg be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
3,ZTS,relative strength rs rating shire shpg jump new percentile wednesday get lift look best stock buy watch factor watch closely be relative price strength ibd unique rating identify market leadership worst best score grade show stock price performance last week compare other stock database year market history show stock go make biggest gain tend have rs rating north begin biggest price move see shire continue show renew price strength hit benchmark look best stock buy watch start hereshire be try complete cup handle buy point see stock clear price volume least average ep growth decrease prior quarter revenue rise prior report next quarterly number be expect company hold rank peer medical ethical drug industry group zoetis zts be top rank stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
4,ZTS,friday zoetis zts get upgrade ibd smartselect composite rating revise score mean stock currently top other stock term key performance metric technical strength winning stock often have higher grade early stage new price run zoetis be currently extend proper buy zone breaking buy point flat base see ibd help make more money stock earn ep rating mean recent quarterly longer term annual earning growth top stock accumulation distribution rating show heavy buy institutional investor last week company post earning growth have now post accelerate ep growth consecutive quarters top line growth climb prior report company have now post rise growth last report zoetis earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related company be now outperform stock
5,ZTS,paycom software payc get plaster seller post result late tuesday much former ibd name zoetis zts be slam more thursday report just few week earlier micron technology mu be send pack shower bat nearly span trading session march good fiscal number sense pattern here month january april july october never fail remind investor stock soar plunge quarterly result peculiar pattern way present challenge stock investor have be trading stock ibd way few month few decade take be just few quarterly result high power growth stock know risk hold big position right news earning result be wall street version double edge sword re smart trader goal maximize profit big winner minimize loss weaker play so consider suggestion help navigate choppy water likely carry more weight now ibd current outlook stand uptrend pressure tip study stock long term character let revisit paycom hr management software firm leaderboard name clear base feb day post exceptional result ep revenue pair key follow buy point come quarterly result first second pullback week move average come week end march june same year however abiom abmd have act differently heart pump firm break long cup handle week end april week share fiscal result more recent past week flat base take place jan year week next quarterly report tip count count count be check number basis stock portfolio have create have stock build third fourth fifth base chance severe post earning slide go reader use pattern recognition service marketsmith save time count basis stock rise least correct entry point primary base top base base form next stage base stock be earning turnaround scoop share early stage likely see more strong quarterly result ahead keep rally humming apple aapl be not ibd play still serve perhaps finest example march quarter iphone giant have now string together straight quarters double digit profit growth not easy firm logged revenue fiscal tip pocket gain way have hear expression bet house money mean ve sell part position winning stock take profit away keep share participate further upside great earning report carry market leader further smart portfolio strategy least snatch partial gain stock rise past most recent point want aim profit sure never forget most pig get slaughter tip check accumulation distribution rating have proprietary measure find stock checkup ibd stock research table weaken recent week so perhaps institution have be dump more share usual lack confidence upcoming month result next quarter outlook rating study price volume interaction past week trade ibd click innovator ibd ffty etf manage innovator fund also follow saito chung twitter ibd_dchung more insight analysis growth stock buy sell rule chart financial market related ibd lesson so far protect best large cap stock today peek big cap market turn always do firstare apple stock market random walk here
6,ZTS,monday shire shpg earn positive adjustment relative strength rs rating look best stock buy watch factor watch closely be relative price strength ibd unique rating identify price movement worst best score grade show stock price performance trail week compare other stock database decade market research reveal best stock tend have rs rating early stage move see shire continue rebound hit benchmark look best stock buy watch start hereshire be work cup handle entry see stock break heavy trading ep growth decline last quarter sale grow previous report next quarterly number be expect company earn rank peer medical ethical drug industry group zoetis zts be top rank stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
7,ZTS,dow jone industrial average index rebound key support level end slightly lower nasdaq composite fuel apple aapl rally tesla tsla skid cash burn elon musk strange conference call mastercard hit buy zone new payment stock struggle alibaba baba pull back strong earning sprint merge mobile tmus headline several big deal job report symmetric fed stance ease rate hike fear crude oil price hit record high shale operator beat earning view dow jone undercut day move average rebound friday finish week nasdaq composite rally retake day line apple aapl fuel earning buyback warren buffett buy more share soar drive major average higher tesla tsla fall alibaba baba rally mastercard enter buy zone treasury yield pull back yield spread narrowing slightly crude oil rise nearly barrel shale earning be strong apparel stock be loser consumer electronic giant apple aapl earn share year year sale fiscal second quarter be best ep gain year latest string accelerate revenue growth report top forecast apple sell iphone just miss consensus service revenue wearable sale be strong apple also announce plan buyback big dividend hike warren buffett disclose berkshire hathaway brkb buy apple share first month bring total stake nearly apple stock surge best weekly gain year hit record high blast buy zone get newsletter deliver inbox more info product service privacy policy term usetesla report smaller expect loss forecast revenue electric car maker model production remain low company burn cash post earning conference call ceo elon musk cut wall street analyst bore question spend next minute take question blogger youtube share fall sharply thursday close week cent alibaba report better expect quarterly earning core commerce revenue swell cloud revenue more double alibaba end quarter monthly active user mobile device alibaba also give bullish outlook share rise friday jobless rate slide april lowest economy add job labor department report friday meanwhile average hourly wage growth rise just year little view fed favore gauge core inflation climb policymaker send message win panic top come month fed stress wednesday inflation target be symmetric qualys qlys fireeye feye fortinet ftnt top earning revenue view share retreat cyberark software cybr rally strong result outlook guide slightly higher meanwhile carbon black cblk jump friday debut ipo price late thursday high end recently raise range zendesk zen pop result guidance show customer support sale automation software company be build momentum rival salesforce com crm larger contract paycom payc report strong earning sale growth forecast line june quarter result send hr payroll process software maker lower fellow payroll hr cloud software firm paylocity pcty break friday result commerce software firm shopify shop top view size sale beat update guidance left investor unimpressed shopify initially fall rebound strong gain ultimate software ulti report adjust ep top estimate revenue grow also beating share rally wednesday close buy point mcdonald mcd surge score double beat ep rise revenue fall shake shack shak sky-rocket friday crushed earning beat revenue wingstop wing also jump friday result taco bell parent yum brand yum earning top share skid weak same store sale yum china yumc tumble weak pizza hut result china offset overall strong earning texas roadhouse txrh slip come par ep cent revenue viper energy partner vnom anadarko petroleum apc concho resource cxo noble energy nbl matador resource mtdr continental resource clr parsley energy pe eog resource eog pioneer natural resource pxd top quarterly estimate integrate energy firm marathon oil mro clear buy point follow earning oil price hit fresh multiyear high inventory production increase odd be rise president trump withdraw iran nuclear pact sprint mobile tmus finally agree merger share fall lack price premium fear antitrust regulator reject deal meanwhile marathon petroleum mpc agree buy andeavor andv create largest base refiner additionally walmart wmt say chain asda merge sainsbury walmart reportedly be deal buy india commerce giant flipkart prologis pld buy dct industrial dct finally marriott vacation vac reveal buy ilg ilg annual developer conference facebook fb say be enter online date business more person facebook identify single match group mtch own match com date app tinder plunge announcement facebook also introduce oculus go stand alone vr headset announce october arista network anet late thursday report ep gain revenue swell beating cisco rival see revenue line view send share tumble friday turnaround project juniper network jnpr late tuesday report ep decline wasn bad expect sale network gear cloud compute customer rebound juniper forecast profit slightly view share pop pare gain allergan agn zoetis zts teva teva exelixis exel top quarterly expectation allergan sank report unlikely make deal zoetis fall adjust profit guidance miss penny dow jone component merck mrk pfizer pfe beat profit lag sale gilead gild miss sale adjust earning hepatitis drug fall vs last year regeneron regn profit beat revenue miss eye drug eylea top view celgene celg topple analyst suggestion key drug be delay year friday celgene say refile application drug ozanimod multiple sclerosis treatment celgene also top first quarter expectation raise full year guidance sarepta srpt sale miss view loss be better expect mastercard share jump credit card giant report earning beat estimate join visa buy range square sq sale also top bitcoin make payment technology firm current quarter profit outlook come short fleetcor flt provide prepay fuel card vehicle fleet other payment product sank low outlook paypal pypl tumble amazon amzn reportedly offer merchant discount use own payment service controversy kanye west comment slavery have tangled adida addyy ceo sportswear company distance not cut ty rapper west yeezy brand be not significant part adida revenue contribute brand style image share tumble buy point adida logging currency neutral revenue growth include solid north america meanwhile armour uaa top estimate give weak outlook susquehanna say inventory be tick time bomb coach kate spade parent tapestry tpr top consensus share plunge upscale purse accessory maker raise guidance be still largely consensus north face van parent vf corp vfc beat view share retreat friday snapchat operator snap snap crash record low miss first quarter view revenue user growth several other key metric grubhub grub top first quarter earning estimate food sale miss target share fall sharply pare loss friday world wrestling entertainment wwe spiked wwe body slam earning estimate continue attract subscriber ep rise cent however revenue be miss disk drive maker seagate technology stx report quarterly earning beat estimate stock fall cautious comment tariff ferrari race zoom buy zone double beat ep rise cent revenue climb tableau datum report sale earning expectation license revenue be ahead consensus company lower full year margin guidance big datum firm stock jump
8,ZTS,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
9,ZTS,adobe system adbe zoetis zts mfs growth fund mfegx have sort lead stock lift portfolio rank top mutual fund additional top stock netflix nflx lululemon athletica lulu amazon com amzn be also big reason fund be groove outperform broad market well large cap growth peer track morningstar inc short intermediate long period range year date year so far year go wednesday fund be vs direct rival big cap bogey netflix be year adobe advanced amazon be lululemon have gain zoetis climb netflix lululemon amazon happen be member leaderboard ibd premium service spotlight play play move top stock ibd take netflix be former stock ibd swingtrader exclusive ibd feature help take advantage short term trend apply rule ibd slim investing system swing trading environment detail past trade be accessible swingtrade subscriber trialist free trial be available paul gordon manage fund eric fischman matthew sabel say fund used classic investment strategy underlie philosophy be time stock follow earning cash say look company grow earning cash flow market average rate economic cycle look company strong competitive position grow industry have pricing power good management team quality characteristic such recur revenue low capital intensity attractive balance sheet fund be patient have long investment time horizon see low annual turnover say fund have not change approach recent market volatility fund add name price dip volatility market sometimes provide opportunity collectively add secular growth company gordon say netflix earning share grow triple digit pace past quarters ibd report tuesday netflix stock gap morning crushed expectation new subscriber growth first quarter guide higher view current quarter stream service push original programming be key strategy netflix have subscriber world gordon say ve have success ramp subscriber real excitement generate january earning call be lack departure customer follow price increase prove market confidence long term pricing power lululemon share price have uptrended nearly year reverse approximately yearlong downtrend issue lululemon face be grow very rapidly number year gordon say take several year reinvest company hurt profitability now seem be come other side gordon add revenue continue increase cost increase slower pace benefit earning growth fund trim modestly recent disclosure gordon describe trim just selectively trimming share price strength amazon gordon say be fire cylinder commerce business continue take significant incremental share retail dollar spend say call amazon web service player space drive cost customer invest new service web service provider need scale add amazon have scale also continue post significant revenue growth say segment amazon commerce business involve third party selling amazon so call business have higher margin growth business sale inventory own amazon gordon say adobe share price barely slip recent market volatility adobe owe resilience leadership status switch subscription revenue sale package software adobe have very strong competitive position grow market gordon say continue experience benefit move subscription base business model mfs team like face zoetis business farm animal medicine business be steady farmer afford lose livestock pet medicine business thrive sentimentality company call humanization pet gordon say dog sleep doghouse now dog sleep bed gordon add zoetis be largest competitor animal health industry grow mid single digit fewer risk human health give be third party payer risk also need much retirement saving age saving more american ever have more
10,ZTS,tuesday zoetis zts get upgrade ibd smartselect composite rating new score indicate company be now outperform stock term most important fundamental technical stock pick criterium zoetis be now buy range clear buy point flat base look winning stock try simple stock earn ep rating meaning recent quarterly annual earning growth top stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company report earning growth top line growth climb prior quarter mark quarter rise revenue gain company next quarterly report be expect feb zoetis hold rank peer medical ethical drug industry group abbvie abbv be rank stock group related company be now outperform stock
11,ZTS,stock post modest gain monday report president trump do not desire trade war china many individual investor top stock mutual fund benefit take ab large cap growth fund apgax ibd best mutual fund award winner fund tack monday gain fund stock be positive territory late afternoon holding finished day gain lead stock hold fund such copart cprt edward lifescience ew zoetis zts global spgi paypal pypl book holding bkng close mostly column copart be edward be slightly lower zoetis be global be paypal be nearly book be stock market warm news report president trump be look avoid trade war china get newsletter deliver inbox more info product service privacy policy term uselead manager frank caruso co manager john fogarty senior research analyst vinay thapar current ibd question answer feature explain stock addition salvage car auctioneer copart say last week expand tuscon ariz location company say expansion boost efficiency buyer seller move enable copart store larger number vehicle also last week online travel agency book holding say have renew agreement obtain pricing book ticket technology travelport tvpt travel commerce platform caruso team like animal drug maker zoetis zts improve gross margin recently stock be member ibd big cap stock list ibd take look pointer invest check ibd investment education page be best mutual fund award winner fund have beaten benchmark past year dec large cap growth other stock mutual fund bogey ve beaten be category only eligible fund manage time feat also enjoy need much retirement saving age income
12,ZTS,stock picker still rejoice friday morning trade casa system casa be astonishing so far year abiom abmd be same period solaredge technology sedg be baozun bzun grubhub grub meanwhile have surrender first quarter
13,ZTS,portfolio feature lead stock atlassian team lululemon athletica lulu autodesk adsk jan oppenheimer discovery mid cap growth fund oegax have outperformed morningstar midcap growth peer group most recent full quarters well so far young year fund manager ronald zibelli jr justin livengood be aim keep outperformance surfing top growth stock look forward expect economy expand faster growth rate faster trajectory last several year due uplift synchronize global recovery manager tell shareholder commentary re bet company think maintain average earning growth matter broad market be do re balancing bet company call high quality emphasize risk management diversification continuous monitoring consistent sell discipline zibelli livengood write impact possible trade war remain be see now so far so good svb financial much silicon valley base bank loan portfolio have float rate so federal reserve raise short term rate svb overall net interest margin be poise increase wednesday fed raise benchmark rate sixth time december central bank signale hasten pace rate hike get newsletter deliver inbox more info product service privacy policy term usein addition large portion svb profit be base revenue benefit trump tax reform lower corporate tax rate svb earning share growth have accelerate increase past quarters svb be stock ibd superregional bank industry group thank trait such project ep gain quarter best possible ibd composite rating stock poise move higher often have comp rating higher still svb enter ibd cut list thursday fizzle atlassian base enterprise software company be leaderboard stock specialize product collaboration business team atlassian show big sale growth recent quarters top line grow vs year level analyst expect price hike atlassian product ibd take atlassion be former stock ibd swingtrader exclusive ibd feature help take advantage short term trend apply rule ibd slim investing system swing trading environment detail past trade be accessible swingtrade subscriber trialist free trial be available lululemon be third leaderboard stock hold fund sale grow most recent quarters totale fiscal company be track reach goal revenue accord ibd market team company have become icon yoga fitness area focus product line result be slate march release close share autodesk be yet ibd leaderboard stock gap march company move cloud compute subscription model paid better expect fiscal fourth quarter ep gain also annualize recur revenue reach quarter increase year year ibd report maker computer aid design software get price target increase least wall street analyst rate buy additional holding zoetis zts maker drug animal benefit strong companion animal segment person be spending more veterinary clinic pet farm animal segment be less growthy more stable do not fluctuate much broader economy speed contract cost vaccine other health product be small compare overall cost run farm also crucial farm maintain health livestock company be better focuse rival be part large more diverse pharmaceutical company ep grow past quarters also top oppenheimer fund be cope blah gdp need much retirement saving age income
14,ZTS,horizon pharma hznp have relative strength rs rating upgrade monday try find best stock buy watch keep close eye relative price strength exclusive rating investor business daily track price performance worst best score rating show stock price movement last week hold other stock database history show best perform stock typically have rs rating north early stage move look winning stock try simple routinehorizon pharma be now consider extend buy range clear buy point first stage double bottom see stock form new pattern follow buy opportunity week tight pullback day week move average earning growth decline last quarter revenue moved higher company hold rank peer medical ethical drug industry group jazz pharmaceutical jazz zoetis zts phibro animal health pahc be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
15,ZTS,jazz pharmaceutical jazz see ibd smartselect composite rating jump thursday day new score mean company be now outperform stock term most important fundamental technical stock pick criterium jazz pharmaceutical be currently extend proper buy zone clear entry consolidation see ibd help make more money stock have ep rating mean recent quarterly longer term annual earning growth top stock accumulation distribution rating show heavy buy institutional investor last week get newsletter deliver inbox more info product service privacy policy term usein company post earning share growth sale growth climb prior quarter mark quarter rise revenue increase jazz pharmaceutical hold rank peer medical ethical drug industry group zoetis zts phibro animal health pahc be also group highest rate stock related company be now outperform stock see stock just come ibd top stock list
16,ZTS,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
17,ZTS,valeant pharmaceutical vrx have relative strength rs rating upgrade monday welcome improvement still shy higher score prefer see try find best stock buy watch keep close eye relative price strength proprietary rating identify technical performance used worst best score identify stock price action trail week compare rest market year market history reveal stock go make biggest gain tend have higher rs rating begin largest climb see valeant pharmaceutical continue rebound hit benchmark look winning stock try simple routinevaleant pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new chart pattern follow buy opportunity week tight pullback day week move average company show earning growth most recent report revenue gain come company be expect report latest performance number company hold rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz abbvie abbv be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
18,ZTS,consider name put watch list look stock higher rs rating horizon pharma hznp just meet criterium new score look best stock buy watch factor watch closely be relative price strength ibd unique rs rating measure market leadership used worst best score indicate stock price performance last week match rest market decade market research show best stock typically have higher rs rating begin biggest price move look best stock buy watch start herehorizon pharma be build double bottom buy point see stock break heavy trade earning growth decrease most recent quarter revenue gain moved higher company earn rank peer medical ethical drug industry group abbvie abbv jazz pharmaceutical jazz zoetis zts be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
19,ZTS,idexx laboratory idxx cater niche clientele keep push back launch next product trade multiple time earning xto investor sound big thank yet wall street pro laud veterinary diagnostic company management brilliant unbelievable grasp business simply put company execution continue be second none raymond james analyst john ransom say recent note client ransom go say further be not often player space dominant approximately market share be able maintain base highly competitive market yet idexx post placement number suggest even be gain share get newsletter deliver inbox more info product service privacy policy term thing niche market question be veterinary market sound small number be fewer veterinarian animal health clinic accord census bureau annually vet serve million very passionate customer pet owner well pet household have pet accord american pet product association translate nearly dog more cat not mention multitude bird fish other creature hang person home most recent annual survey reveal dog owner spend annual average routine surgical vet visit combine cat owner shell idexx be industry leader supply vet technology run clinic test blood work cater primarily beloved canine feline abroad raymond james ransom canaccord genuity analyst mark massaro peg company stateside market share hefty player abaxis abax have corner quarter american market smaller competitor heska hska have tenth vca unit antech diagnostic zoetis zts latter be acquire abaxis also number rival water treatment livestock product account sliver idexx revenue big money come companion animal diagnostic business include suite clinic product such chemistry panel rapid test kit veterinary instrument analyzer be also external laboratory service such diagnostic imaging testing companion animal diagnostic unit bring idexx more net revenue overall haul year person simply take pet vet be likely result idexx test equipment be used kind diagnostic test be administer time person bring fluffy friend clinic idexx say investor day presentation last august pet owner tend not object fact millennial pet owner be more likely older peer say money be object come pet accord idexx survey work percent year old feel way vs gen xer baby boomer younger person get laser focuse career longer get married have kid go get dog year old say massaro millennial say be prioritize pet other thing maybe person generation hold greater esteem idexx most recent quarter be laud analyst share profit rise share revenue grow top view cent respectively accord zack investment research company have see success sedivue industry first clinic urine sediment analyzer recently launch product catalyst sdma clinic test used vet look kidney disease be adopt north american customer first few month debut idexx chief executive ayer contend amazing amazing accomplishment nothing happen fast veterinary tell analyst call adoption rate be typically very slow context adoption sdma slide have be exceptional so re very very pleased success ve have quarterly beat reinforce piper jaffray bullish call companion animal industry william blair analyst say believe long term investment merit idexx remain very compelling beat single line single reference category say canaccord genuity massaro add get extremely strong commercial execution idexx have most savvy sale organization ve ever see point company unusually large direct sale force sale rep north america more europe particular strength share idexx end trading thursday close barely remain buy point share be marginally friday break sharply cup handle base high volume follow company earning report management also lift full year earning guidance cent organic revenue outlook growth currency neutral basis reaffirm sale outlook adjust exchange rate growth even raymond james ransom have high praise company only reaffirm market perform rating same note client cite high price earning multiple hindrance more positive rating come idexx have more occasion push back launch snap fecal dx allow vet test house presence hookworm whipworm roundworm infection canaccord massaro brushed delay view idexx continue crush number raise guide product launch come tell street re beating number startling idexx consistently trade almost time premium multiple other good health care company say massaro example hologic holx medical imaging company call undisputed leader mammography trade time earning vs idexx time earning idexx consistent beat raise quarters model nearly recur revenue unusually high health care number bolster confidence idexx management team have unbelievable grasp business say william blair analyst ryan daniel believe company be durable business franchise warrant premium multiple write early firm be more aggressive share purchase pullback more broadly raymond james ransom say april investor shouldn expect growth ramp end market companion animal diagnostic mean share company idexx abaxis heska be more likely move individual success share gain new product launch etc move uniformly encompass cyclical dynamic give baseline growth rate animal health diagnostic industry canaccord genuity massaro say mean even worst company space grow year really be spectacular industry say be interested medtech stock break zoetis snag billionstock show improve market leadership idexx laboratory earn rs ratingthis top medical stock break beat raise
20,ZTS,keep list stock watch date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock add remove list include planet fitness ticker
21,ZTS,look best stock buy watch focus rise relative price strength stock fit bill be abbvie abbv have relative strength rs rating upgrade wednesday re research best stock buy watch be sure pay attention relative price strength ibd proprietary rating identify market leadership worst best score grade show stock price behavior last week compare other stock database year market history reveal best perform stock tend have rs rating north early stage move see ibd help make more money stocksabbvie be not currently offer proper buy opportunity see stock go build chart pattern launch new move term fundamental company have post quarters accelerate earning growth revenue gain have also increase same period abbvie be expect report next quarterly number apr abbvie earn rank peer medical ethical drug industry group zoetis zts be rank stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
22,ZTS,relative strength rs rating astrazeneca azn moved new percentile monday get lift re research best stock buy watch keep close eye relative price strength ibd proprietary rs rating identify market leadership show stock price action last week measure other stock database history reveal stock go make biggest gain often have rs rating north begin largest price move see astrazeneca continue show renew price strength hit benchmark look best stock buy watch start hereastrazeneca be work cup handle buy point see break heavy trade earning growth increase last quarter top line fall next quarterly number be expect apr company hold rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz nordisk nvo be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
23,ZTS,wednesday horizon pharma hznp get upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength unique rating identify market leadership show stock price action last week measure other stock database history show best stock typically have better rs rating early stage move look winning stock try simple routinehorizon pharma be try complete consolidation buy point see break heavy volume ep growth decline company latest report top line rise horizon pharma hold rank peer medical ethical drug industry group zoetis zts abbvie abbv phibro animal health pahc be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
24,ZTS,abbvie abbv see improvement ibd smartselect composite rating wednesday upgrade mean stock be now outpace other stock term key performance metric technical strength market biggest winner often have higher score early stage new price run so good item have checklist look best stock buy watch abbvie be currently entry flat base look winning stock try simple stock earn ep rating mean recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show roughly equal amount buy selling institutional investor last week get newsletter deliver inbox more info product service privacy policy term usein company post earning growth have now post accelerate ep increase consecutive quarters top line growth increase prior report company have now post rise growth last report abbvie earn rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz be also group highest rate stock related company be now outperform stock see stock just come ibd top stock list
25,ZTS,important metric look stock be higher relative strength rating abbvie abbv now clear threshold jump wednesday re research best stock buy watch keep close eye relative price strength exclusive rating investor business daily track market leadership worst best score score show stock price performance last week stack other stock database year market history reveal best stock tend have higher rs rating launch biggest price move see ibd help make more money stocksabbvie be try complete consolidation buy point see stock break heavy volume later stage pattern investor be aware involve more risk term top bottom line number company have post quarters accelerate earning growth revenue gain have also rise same time frame abbvie earn rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz be also group highest rate stock get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
26,ZTS,horizon pharma hznp have relative strength rs rating upgrade thursday welcome improvement still higher score prefer see ibd unique rs rating measure technical performance show stock price action last week compare other stock database history reveal best stock often have rs rating north launch largest price move see horizon pharma continue show renew price strength clear threshold look best stock buy watch start herewhile stock be not proper buy point right now see be able form break proper chart pattern earning growth drop company most recently report quarter revenue grow prior report look next report feb company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts jazz pharmaceutical jazz be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
27,ZTS,relative strength rs rating astrazeneca azn climb higher percentile monday get lift ibd unique rs rating identify market leadership show stock price movement last week measure other stock database history reveal best stock tend have better rs rating begin largest run see astrazeneca continue rebound clear threshold look winning stock try simple break earlier have fall back prior entry consolidation stock re tracking clear buy point then retreat more original entry price consider fail base stock set new chart pattern entry price also keep mind most recent pattern be later stage base involve more risk revenue growth fall last quarter ep grow previous report astrazeneca earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
28,ZTS,here weekly investing action plan need know investor come week much earning even matter stock market be still seize terror next week lock sell mode estimate beating number produce day lift anyone guess happen bear stay
29,ZTS,relative strength rs rating novartis nvs head higher percentile friday get lift ibd proprietary rating identify market leadership worst best score score show stock price movement last week compare other stock database decade market research show best stock tend have rs rating north early stage move see novartis continue show renew price strength hit benchmark see ibd help make more money stocksnovartis be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week line top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase novartis hold rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
30,ZTS,abbvie abbv have relative strength rs rating upgrade friday try find best stock buy watch keep close eye relative price strength ibd proprietary rating measure market leadership worst best score rating show stock price movement trail week hold other stock database history reveal market biggest winner tend have rs rating begin biggest run look winning stock try simple routineabbvie be not currently offer proper buy opportunity see stock go form promising consolidation spark new run term fundamental abbvie have post rise ep growth last quarters revenue growth have also increase same time frame company hold rank peer medical ethical drug industry group zoetis zts be rank stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
31,ZTS,dirty little secret investing sort study show pretty woman handsome man be more likely be hire someone be ugly stock be different stock be forgive chart flaw more readily fundamental be not just good beautiful different rule different folk well yes say life be fair netflix nflx be good example beautiful stock earning grow last year be expect surge year stock break january then advanced more march high meanwhile nasdaq score intraday high day netflix high nasdaq then correct netflix fall almost stock have so so fundamental then bigger average pullback be regard serious flaw hot growth stock sharper correction be accept quicker rebound be expect get newsletter deliver inbox more info product service privacy policy term usethere more netflix decline stop day move average stock bounce line tuesday add nice cushion be netflix first trip day line january bounce provide secondary entry do volume be quiet rebound wednesday turnover be average be spike volume sufficient create buy area many investor say yes netflix fundamental be beautiful share have continue climb netflix return equity gauge financial efficiency be almost last year best year annual sale jump year growth rate street expect sale jump year netflix report result monday close market new uptrend create more buy candidate bull corral netflix be other big cap several stock be well position possible buy let look chart fundamental cloud base tech software developer servicenow now be tough read chartwise stock have make multiple trip day line july however chart reader interpret consolidation oct mid december flat base then recent trip day line be first prudent interpretation be treat stock extend servicenow grow earning past year other stock show promise be online brokerage trade financial etfc robotic surgery equipment maker intuitive surgical isrg drugmaker zoetis zts annual ep growth stock be good not pretty related millionaire be more common daysold advice be true advice follow rule investingwhen sell great stock make money
32,ZTS,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
33,ZTS,earning season full swing market stalwart apple aapl report fiscal result close today positive earning surprise be provide catalyst number strong breakout report earning result stock be notch new week high stock market today xyum brand yum surge
34,ZTS,valeant pharmaceutical vrx have relative strength rs rating upgrade tuesday ibd proprietary rs rating track market leadership show stock price movement last week compare other stock database history reveal market biggest winner typically have rs rating begin new climb see ibd help make more money stocksvaleant pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average valeant pharmaceutical report negative growth sale earning last quarter company earn rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
35,ZTS,valeant pharmaceutical vrx see positive improvement relative strength rs rating thursday rise ibd proprietary rs rating track market leadership used worst best score show stock price performance last week match other stock history reveal best stock tend have higher rs rating launch biggest climb look winning stock try simple routinevaleant pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average company report negative growth sale earning last quarter company earn rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
36,ZTS,ibd stock list be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
37,ZTS,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap stock watch
38,ZTS,ab large cap growth apgax be elite group top mutual fund be ibd best mutual fund award winner top mutual fund beat benchmark past year dec take extraordinary consistency large cap growth other stock mutual fund bogey ve beaten be category only eligible fund manage time feat more impressively ab large cap growth outperformed time period category diversify equity fund growth fund large cap fund hard be gain entry winner circle only eligible diversify stock fund make best mutual fund award list become top mutual fund lead manager frank caruso co manager john fogarty senior research analyst vinay thapar have assemble diversify portfolio include lead stock auto part health care financial technology such copart cprt edward lifescience ew zoetis zts global spgi nvidia nvda hold period vary stock past month have rise edward global zoetis copart nvidia get newsletter deliver inbox more info product service privacy policy term usestill caruso team have be trimming lead stock grow competitive threat caruso describe stock have reservation meanwhile overall find stock persistently outperform market depend caruso say find idiosyncratic opportunity invest year old caruso colleague fogarty thapar discuss other aspect team investment approach ibd office manhattan ibd portfolio be ibd best mutual fund award winner do take outperform so consistently period short month year frank caruso focus look business not stock be attract business differentiate competitive position company produce higher average level profitability profitability exceed fair cost capital here secret sauce start look good business then obsess company idiosyncratic opportunity invest earn high return capital ibd exactly do mean idiosyncratic opportunity invest caruso be investment opportunity be company specific occur company take action put upward pressure profitability take nike nke ve be chasing low cost labor noticed patent filing look new manufacturing technology build shoe robotize machine build plant closer consumer save tariff duty shipping ibd fund be fairly concentrated just stock jan do prefer concentrated approach caruso first think re good research company want get paid research second have name allow get exposure larger cap company also seed portfolio sometimes younger more exciting company be small end portfolio size range have be low mid sixty first take portfolio be still shape portfolio vision ibd auto auctioneer copart be smaller name market cap have post straight quarters earning share growth acceleration driver caruso re probably not type business lot growth portfolio have high profitability be high versus cost capital yet surprisingly stable secular trend give confidence sustainability performance be auto become more complex lead more attractive salvage rate more more car too expensive repair one get damage so copart supply inventory get bigger ibd begin current stake august then caruso multiyear period copart infrastructure do not perform efficiently exploit new inventory arise due hurricane so company invest money upgrade capability august hurricane season investor question copart have do enough lower copart share price buy uncertainty ibd most part ve be build stake edward lifescience vinay thapar pioneer development transcatheter aortic valf patient have do open heart surgery go bypass machine have valf repair edward get engineering product be insert snake catheter artery leg be far more minimally invasive result faster discharge hospital average patient cost be less open heart procedure yet product have higher average gross margin operate margin expect uplift return company invest capital roic have occur roic be close upper echelon other company company forecast market be only now re look used same procedure different valve mitral valve be new market ibd zoetis be name ve be build stake fuel interest thapar re leader pharmaceutical animal health thesis be pfizer have opportunity improve operate performance right size number skus item sale close manufacturing facility improve gross margin commit investing higher return project single digit top line growth market growth rate cost improvement have lead higher return go forward pipeline product be yet be reflect stock price ve commit reduce inventory balance improve return invest capital ibd global be hold ep growth have accelerate have happened caruso re modele annual revenue growth area next year low single digit earning growth index business have be big part success rating business be best class franchise low rate environment good level volatility expectation be increase world rating business benefit maybe part index business ibd ve be nvidia long time do story have much runway left front caruso be portfolio graphical chip have find new application think ai artificial intelligence think hyperscale datum center think vr virtual reality think auto vision nvidia gpus be general purpose chip think be application specific chip early stage company become competitive market share next month so ve be trimming position ibd book holding bkng be priceline new name do particular online travel agency john fogarty change name reflect primary asset online travel portfolio appeal be dominant position europe hotel market be far more fragmented industry be dominate chain book take advantage europe fragmentation so enjoy higher commission rate result ibd paypal pypl be relative newcomer portfolio do introduce fogarty begin buy fourth quarter growth paypal be essentially ride increase adoption online payment particular mobile payment re attract rise return asset trajectory not just growth increase profitability ibd anyone want add comment caruso john summarize thought paypal take market share expect grow high teen next year complement visa exposure ibd take paypal be former stock ibd swingtrader exclusive ibd feature help take advantage short term trend apply rule ibd slim investing system swing trading environment detail past trade be accessible swingtrader subscriber trialist free trial be available also nike facebook frank caruso project long term earning need much retirement saving age incomebond mutual fund help steadier long term interest rate
39,ZTS,valeant pharmaceutical vrx see welcome improvement relative strength rs rating wednesday rise ibd proprietary rating measure share price action worst best score rating show stock price performance last week stack other stock database history reveal stock go make biggest gain tend have rs rating north begin biggest price move see valeant pharmaceutical continue show renew price strength clear threshold look best stock buy watch start herevaleant pharmaceutical have moved more past entry first stage cup handle meaning now proper buy range look stock offer new chance get week tight pullback day week line company post negative growth sale earning last quarter company earn rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
40,ZTS,monday valeant pharmaceutical vrx earn positive adjustment relative strength rs rating ibd unique rs rating measure market leadership show stock price movement last week measure other stock database history show market biggest winner tend have higher rs rating early stage move see valeant pharmaceutical continue show renew price strength clear threshold see ibd help make more money stocksvaleant pharmaceutical have climb more past entry first stage cup handle meaning now proper buy zone look stock offer new chance pick share week tight pullback day week line valeant pharmaceutical report negative growth sale earning last quarter company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
41,ZTS,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
42,ZTS,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
43,ZTS,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
44,ZTS,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
45,ZTS,astrazeneca azn see positive improvement relative strength rs rating thursday rise look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure price action worst best score grade show stock price performance last week hold other stock database year market history show stock go make biggest gain often have rs rating launch largest price move see astrazeneca continue show renew price strength clear threshold see ibd help make more money be work cup handle entry see clear price volume least higher normal earning growth increase last quarter sale fall company be expect report latest result apr company hold rank peer medical ethical drug industry group zoetis zts abbvie abbv jazz pharmaceutical jazz be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
46,ZTS,ibd stock list be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap stock list
47,ZTS,relative strength rs rating astrazeneca azn climb new percentile wednesday get lift ibd proprietary rs rating track technical performance used worst best score indicate stock price action trail week compare other publicly trade company history show best stock typically have higher rs rating begin largest price move see astrazeneca continue rebound hit benchmark look winning stock try simple be build consolidation buy point see stock break volume least average earning growth drop last quarter revenue rise astrazeneca earn rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
48,ZTS,zoetis zts see positive improvement relative strength rs rating friday rise proprietary rating measure market leadership show stock price movement last week measure other stock database history reveal best stock tend have higher rs rating begin biggest run zoetis be still buy range climb entry flat base once stock move higher original entry consider extend buy range relative strength line have moved new high territory positive sign market leadership company show ep growth last quarter sale growth come company hold rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
49,ZTS,tcw select equity fund tcgex be enjoy big rebound thank steadfast focus lead stock amazon com amzn mastercard zoetis zts not only be poise future growth have climb respectively year xlast year fund lag nearly entire large cap growth peer group track morningstar direct year rally fund year date gain go thursday top direct rival well advance fit fund long term outperformance challenge last year be market rotate value oriented stock material industrial energy financial away more growth oriented stock fund manager craig blum like struggle have pretty much unwound blum say re not hoisting trophy ve get rest year go re proud have deliver upside shareholder be way recover past year fund be top peer outran peer even fund fall fund stick knit never change approach blum say stay resolute focus quality stock growth portfolio name june focus be right way describe portfolio range name aim company capable long term price appreciation earning growth quality part equation want company capable durable sustainable earning growth have wide moat business be capture market share have balance sheet strength blum say technology sector be blum be look lot stock now have tech weighting aug find lot disruptive force say want large opportunity many tech company have large total addressable market amazon be tech name commerce cloud service giant be still top hold june even blum make small trim recent disclosure work long term short term price target say amazon be short term target add feel quite confident long term thesis add amazon spending fulfillment center expansion aggressive investment amazon web service aw be justified more big enterprise be shift datum center operation service aw say long term spending be value accretive say say whole food acquisition be not related amazon trim be constructive whole food acquisition long term variety reason say call takeover opportunity speed amazon prime membership sign up also big increase amazon distribution fulfillment capability ibd take amazon be ibd leaderboard ibd premium service spotlight play play top stock emerge amazon strength be be become consumer electronic maker own right popular echo digital assistant product mastercard be relative newcomer blum begin buy january blum call stock be member ibd list stock have strong relative price strength fundamental attractive play growth commerce card penetration blum also own visa like mastercard outlook slightly better have more room grow mastercard be develop technology advertising service successful be new source revenue earning growth be develop technology enable bank wring more information stodgy automate clear house network bank use manage service such process payroll direct deposit tax payment consumer bill money transfer account zoetis be newcomer blum begin buy growthier part business be companion animal segment blum say secular trend folk spending more veterinary clinic pet farm animal segment be more stable blum like do not fluctuate much broader economy speed contract cost vaccine other health product be small compare overall cost run farm also crucial farm maintain health livestock also blum say company be better focuse rival be part large more diverse pharmaceutical company rival aren able integrate marketing research development way zoetis be blum say focus be competitive advantage durability revenue earning be something blum value several holding appropriate maintain balanced view say good combine higher beta more aggressive growth company more defensive name zoetis never know recession start average business cycle have last month say re now month re cyclically bullish short term eye be wide open midterm related join lawsuit mushrooming equifax hack be newcomer stock investing want few pointer check need much retirement saving age income
50,ZTS,tuesday horizon pharma hznp get positive adjustment relative strength rs rating look best stock buy watch factor watch closely be relative price strength unique rating identify market leadership show stock price movement last week compare other stock database year market history show best perform stock tend have better rs rating begin biggest run look best stock buy watch start herenow be not ideal time jump isn proper buy zone see stock manage offer clear appropriate buy point sale growth fall last quarter bottom line grow prior report horizon pharma earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
51,ZTS,thursday horizon pharma hznp earn upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track market leadership worst best score score show stock price behavior trail week stack other stock database history reveal best stock often have rs rating least early stage move see horizon pharma continue rebound clear threshold look best stock buy watch start herehorizon pharma be not currently show potential entry point see stock go build promising consolidation kick new climb earning growth increase company latest report top line fall horizon pharma earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
52,ZTS,build watch list look stock higher rs rating bristol myer squibb bmy just meet criterium new score ibd proprietary rs rating measure market leadership show stock price movement last week compare other stock database year market history reveal market biggest winner tend have rs rating least early stage move see ibd help make more money stocksbristol myer squibb have moved more past entry first stage flat base meaning now proper buy zone look stock create new chance pick share week tight pullback day week line earning growth increase last quarter top line fall bristol myer squibb earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
53,ZTS,end summer blahs elevated geopolitical uncertainty take toll stock market stock mutual fund august notch first loss year xafter have fall nearly mid august broad stock market form rally close month gain be lift such lead stock dow jone industrial stock visa unitedhealth group unh well technology leader grubhub grub lag diversify stock mutual fund lose average large cap growth fund do best tack small cap value fund do worst lose overall investor generally tread water august say david joy chief market strategist ameriprise financial amp good news pretty much offset bad news market do not turn decisively way broad benchmark modest gain extend market winning streak month edge gain year date diversify stock fund be left year date return mutual fund manager speak ibd expect many opportunity new gain come technology innovator quality company firm capable churn earning growth even slow economic growth environment factor hearten investor last month include weak dollar boost export say manager daniel strickberger touchstone large company growth fund tsagx top large cap growth peer track morningstar direct august addition manufacturing show strength base monthly institute supply management report overall employment post gain less july retail sale consumer sentiment be pretty good joy say negative factor include soft inflation number be sign tepid overall economic growth defeat health care reform signale tax reform infrastructure spending be uncertain joy say geopolitical tension involve north korea contribute investor skittishness strickberger say addition low inflation help persuade federal reserve slow interest rate hike interest rate be head be month say stephen dufour manager fidelity focuse stock fund ftqgx top large cap growth rival last month long run fall rate usually help utility hurt financial contrast diversify stock mutual fund world stock mutual fund eke gain august latin american fund lead charge rise many investor seek safe haven last month taxable bond fund general advanced average be lead treasury bond mutual fund gain muni fund also advanced average precious metal stock mutual fund top sector fund category rac advance august market blahs ameriprise joy be guardedly optimistic go forward economic growth remain muted positive say global growth least develop market be strongest recession many foreign central bank be continue monetary policy support stock expect large business continue benefit weak dollar least year end model portfolio ameriprise recommend financial advisor client remain overweight technology sector general still have room run joy say model portfolio weighting emerge market stock have also be boost be still underweight china remain strong latin american economy be heal say fidelity dufour also see attractive trend tech sector digital advertising electronic payment growth exchange trade fund etfs be area get excited say cite holding july digital advertising name have stake be adobe system adbe business model have morphed used sell program computer disk brick mortar retailer customer have upgrade buy new disk few year ve evolved software service pay monthly basis ve always get access latest version program dufour say once create digital product adobe also monitor online traffic attract help client manage online advertising campaign addition have commercial image library multiservice approach position adobe benefit growth digital medium online advertising dufour say paypal pypl be grow growth electronic payment world dufour say have do good job increase number place paypal have higher percentage online transaction physical store one online commerce grow expense physical store be net gainer paypal also own venmo be payment service let user divvy payment share good service be popular millennial global spgi be poise benefit growth etfs company have exit education book ownership businessweek focus area company provide datum client area consist index customer state street global advisor ssga license etfs build operate global business be very exciting have very substantial margin dufour say other sector touchstone strickberg cite zoetis zts sort quality predictable growth company want company prosper gdp growth be say roughly half sale developer animal medicine vaccine be livestock rather pet commercial agricultural sale don fluctuate much economic up down steadiness make kind business look strickberger say vanguard primecap core vpccx large cap growth fund ibd best mutual fund award winner edge last month own asml hold asml dutch maker lithography system used create computer chip share have climb year stock have very strong composite rating ibd smr rating score scale stock poise move higher often have comp rating higher ibd take asml smr rating mean semiconductor equipment maker be top stock term sale growth profit margin return equity ratio base ibd proprietary formula buy stock high smr rating proper buy point increase chance investment success related here easy routine get start stock investingwhat stock market do now investor turn more defensive even market rise again
54,ZTS,stock market close mixed thursday dull session belie number bullish breakout top rank stock nasdaq composite rise dow jone industrial average fall ease fraction index close day move average area chart reader be watch sign support small cap russell fall nearly dow utility lead increase volume rise board accord preliminary figure sleepy session see financial stock lag badly several stock rise past buy point low volume left doubt kbr kbr break imperfect cup handle base surge past buy point heavy volume company provide engineering consult service defense aerospace addition service energy company jeld wen jeld rise buy point double bottom base heavy trading company largest maker window door gap wednesday aim today jeld wen go public jan share ebay ebay break cup handle base active trading commerce stock be buy range buy point boston scientific bsx climb buy point flat base volume be hardly average be blemish otherwise look good base have tight price behavior relative strength line make new high well boston scientific major provider medical device wasn only stock medical sector break zoetis zts break flat base surge past buy point volume be lackluster end right average daily turnover share zoetis make veterinary vaccine medicine diagnostic other product have middling ep rating thinly trade korn ferry international kfy clear buy point base close entry still share jump time average volume staffing service company beat profit expectation july end quarter related disney warn profit keep star war marvel netflixibd rating upgrade ebay flash improve relative price strength
55,ZTS,build watch list look stock higher rs rating jazz pharmaceutical jazz just clear benchmark upgrade ibd unique rating track share price performance worst best score score show stock price movement trail week hold other stock database decade market research show market biggest winner typically have rs rating early stage move stock be work flat base buy point see clear price volume least higher normal jazz pharmaceutical show ep growth most recent report sale growth come company earn rank peer medical ethical drug industry group abbvie abbv nordisk nvo zoetis zts be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
56,ZTS,horizon pharma hznp have relative strength rs rating upgrade tuesday welcome improvement still short higher score look ibd proprietary rs rating identify technical performance used worst best score indicate stock price performance last week match other stock year market history show stock go make biggest gain typically have higher rs rating begin largest run see horizon pharma continue rebound hit benchmark see ibd help make more money stocksnow be not ideal time jump isn proper buy zone see stock manage form base break ep growth drop prior quarter top line grow prior report look next report feb company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
57,ZTS,here investing action plan thursday need know investor come day several highly rate company report tomorrow include cisco csco rival arista network anet rank ibd logmein logm shopify shop global payment gpn key economic indicator be also due arista network provider
58,ZTS,zoetis zts see welcome improvement relative strength rs rating tuesday rise exclusive rating investor business daily track share price action worst best score grade show stock price behavior trail week stack other stock database decade market research show market biggest winner typically have rs rating north begin biggest climb look best stock buy watch start herezoetis have rise more past entry first stage flat base meaning now proper buy zone look stock offer new chance get week tight pullback day week line earning grow last quarter prior report revenue also increase zoetis earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
59,ZTS,novartis nvs see positive improvement relative strength rs rating friday increase ibd proprietary rating measure price movement worst best score grade show stock price movement trail week stack other stock database history show best stock typically have better rs rating launch biggest price move see novartis continue rebound hit benchmark stock be work flat base buy point see stock break volume least higher normal earning growth increase last quarter sale fall company earn rank peer medical ethical drug industry group abbvie abbv nordisk nvo zoetis zts be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
60,ZTS,tuesday zoetis zts hit important technical benchmark relative strength rs rating enter percentile improvement day proprietary rating track technical performance used worst best score indicate stock price action trail week match other publicly trade company year market history reveal best stock often have higher rs rating begin biggest price move zoetis be try complete flat base buy point see clear price heavy volume company show earning growth latest quarterly report sale growth come zoetis hold rank peer medical ethical drug industry group nordisk nvo be top rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
61,ZTS,zoetis zts have relative strength rs rating upgrade tuesday welcome improvement still shy better score prefer see ibd unique rating identify price performance worst best score grade show stock price performance trail week compare other stock database history reveal stock go make biggest gain tend have better rs rating launch largest run see zoetis continue rebound clear threshold zoetis be build flat base buy point see clear price heavy trading zoetis report earning growth most recent report sale rise zoetis earn rank peer medical ethical drug industry group nordisk nvo be rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
62,ZTS,horizon pharma hznp have turn nearly deal year continue hunt drug acquisition ub say friday raise price target horizon pharma stock well revenue estimate research report ub analyst marc goodman ami fadium write track record balance sheet
63,ZTS,next week bring passel earning report large cap drugmaker biotech pharma stock be trading new high yet again novartis bristol myer squibb eli lilly valeant pharmaceutical abbvie biogen be tap busy earning week here quick rundown be especially big week news biogen biib
64,ZTS,very different similarly high rate medical stock report strong quarterly earning tuesday morning drive stock
65,ZTS,smallest hottest be device maker abiom abmd jump new high early trading soundly beating wall street expectation raise guidance bit later abiom stock be
66,ZTS,abiom earning fiscal end march totale cent share exclude time item be just cent year earlier quarter cent analyst consensus accord thomson reuter sale rise street average estimate
67,ZTS,full fiscal sale rise profit jump cent share abiom add fiscal sale guidance now do not issue ep guidance say expect operate profit margin range
68,ZTS,beat be especially notable give launch firm new impella rp heart pump be dampen snowstorm northeast quarter cancele most training session require physician used impella risky heart procedure growth also come ahead march expand fda approval impella let abiom market device physician restriction ceo mike minogue say conference call analyst tuesday such marketing effort have swung high gear mobile learn lab double wide trailer travele country sort door door expo booth
69,ZTS,cfo robert bowen say guidance do not include sale japan expect impella launch late fiscal year bowen say company update guidance include later year
70,ZTS,mallinckrodt hike guidance
71,ZTS,abiom stock boast highest possible ibd composite rating do mallinckrodt mnk specialty drug maker also report good quarter early tuesday earning jump share beating consensus cent revenue climb
72,ZTS,mallinckrodt add cent full year ep guidance range now vs last year sale guidance be now higher previously vs last year
73,ZTS,conference call analyst ceo mark trudeau admit certain nonrecurring benefit boost generic drug sale quarter growth key immunology drug acthar be anemic however reiterate belief long term potential product say only potential patient believe benefit approve indication be currently be treat
74,ZTS,untapped potential believe double number patient acthar longer term say
75,ZTS,mallinckrodt stock be early trading stock market today
76,ZTS,zoetis cut cost
77,ZTS,animal health giant zoetis zts announce yet quarterly beat also massive cost cut program company earning rise year earlier quarter cent share top street consensus cent revenue be flat line consensus most other global player quarter firm take big hit foreign exchange rate constant currency sale grow earning
78,ZTS,fx headwind reduce business venezuela lead zoetis cut full year sale guidance now maintain previous operate ep guidance
79,ZTS,zoetis also announce comprehensive operational efficiency initiative include cut various cost unload lower margin product firm say lower revenue boost profit latter effect win be apparent year offer ep guidance well street current estimate
80,ZTS,much better longer term margin operate margin vs consensus be drive additional cost save initiative write evercore isi analyst mark schoenebaum email client also company provide specific cog cost good sell guidance vs previously announce long term initiative basis point improvement cog guidance
81,ZTS,large mature player zoetis hasn be grow fast smaller company still hold excellent composite rating open tuesday zoetis stock rise more later be just fraction
82,ZTS,follow amy reeve twitter ibd_areeve very different similarly high rate medical stock report strong quarterly earning tuesday morning drive stock smallest hottest be device maker abiom abmd jump new high early trading soundly beating wall street expectation raise guidance bit later abiom stock be abiom earning fiscal end march totale cent share exclude time item be just cent year earlier quarter cent analyst consensus accord thomson reuter sale rise street average estimate full fiscal sale rise profit jump cent share abiom add fiscal sale guidance now do not issue ep guidance say expect operate profit margin range beat be especially notable give launch firm new impella rp heart pump be dampen snowstorm northeast quarter cancele most training session require physician used impella risky heart procedure growth also come ahead march expand fda approval impella let abiom market device physician restriction ceo mike minogue say conference call analyst tuesday such marketing effort have swung high gear mobile learn lab double wide trailer travele country sort door door expo booth cfo robert bowen say guidance do not include sale japan expect impella launch late fiscal year bowen say company update guidance include later year mallinckrodt hike guidanceabiom stock boast highest possible ibd composite rating do mallinckrodt mnk specialty drug maker also report good quarter early tuesday earning jump share beating consensus cent revenue climb mallinckrodt add cent full year ep guidance range now vs last year sale guidance be now higher previously vs last year conference call analyst ceo mark trudeau admit certain nonrecurring benefit boost generic drug sale quarter growth key immunology drug acthar be anemic however reiterate belief long term potential product say only potential patient believe benefit approve indication be currently be treat untapped potential believe double number patient acthar longer term say mallinckrodt stock be early trading stock market today zoetis cut costsanimal health giant zoetis zts announce yet quarterly beat also massive cost cut program company earning rise year earlier quarter cent share top street consensus cent revenue be flat line consensus most other global player quarter firm take big hit foreign exchange rate constant currency sale grow earning fx headwind reduce business venezuela lead zoetis cut full year sale guidance now maintain previous operate ep guidance zoetis also announce comprehensive operational efficiency initiative include cut various cost unload lower margin product firm say lower revenue boost profit latter effect win be apparent year offer ep guidance well street current estimate much better longer term margin operate margin vs consensus be drive additional cost save initiative write evercore isi analyst mark schoenebaum email client also company provide specific cog cost good sell guidance vs previously announce long term initiative basis point improvement cog guidance large mature player zoetis hasn be grow fast smaller company still hold excellent composite rating open tuesday zoetis stock rise more later be just fraction follow amy reeve twitter ibd_areeve
83,ZTS,bristol myer squibb bmy see positive improvement relative strength rs rating friday rise unique rating identify technical performance show stock price movement last week measure other stock database decade market research reveal stock go make biggest gain often have rs rating north launch largest run see bristol myer squibb continue show renew price strength clear threshold look best stock buy watch start herebristol myer squibb be build flat base buy point see stock clear price volume least average revenue growth fall last quarter ep grow prior report company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
84,ZTS,relative strength rs rating astrazeneca azn jump new percentile friday get lift ibd unique rs rating track market leadership used worst best score indicate stock price performance trail week stack other stock database year market history reveal stock go make biggest gain tend have rs rating least begin largest price move see astrazeneca continue rebound clear threshold look best stock buy watch start herewhile not currently ideal time jump see stock be able form base break earning growth rise last quarter sale fall company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
85,ZTS,grifol grfs have relative strength rs rating upgrade thursday welcome improvement still better score prefer see exclusive rating investor business daily track price action worst best score grade show stock price performance last week hold other stock database year market history reveal best stock typically have better rs rating begin largest run see grifol continue rebound hit benchmark see ibd help make more money stocksnow be not ideal time jump isn proper buy zone see stock be able offer clear appropriate buy point grifol post ep growth most recent report sale growth come look next report mar company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts jazz pharmaceutical jazz be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
86,ZTS,welcome move sanofi sny see relative strength rating improve friday ibd unique rating identify market leadership worst best score grade show stock price movement last week stack other stock database year market history show stock go make biggest gain typically have rs rating north early stage move see sanofi continue show renew price strength clear threshold stock be try complete flat base buy point see stock clear price volume least higher normal term top bottom line number company have post rise ep growth last quarters revenue gain have also moved higher same time frame company earn rank peer medical ethical drug industry group nordisk nvo phibro animal health pahc zoetis zts be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
87,ZTS,valeant pharmaceutical vrx see welcome improvement relative strength rs rating tuesday rise ibd unique rs rating measure technical performance show stock price action last week compare other stock database history show market biggest winner often have rs rating begin biggest run see valeant pharmaceutical continue rebound clear threshold now be not ideal time invest see stock be able form base break earning sale growth come respectively latest report marked quarter acceleration earning revenue valeant pharmaceutical hold rank peer medical ethical drug industry group jazz pharmaceutical jazz zoetis zts phibro animal health pahc be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
88,ZTS,stock extend loss tuesday afternoon heighten north korea related geopolitical tension xspdr dow jone industrial average dium powershare qqq trust qqq tumble spdr spy give stock market today emerge market lead downside ishare msci emerge market eem sank country etfs ishare msci south korea capped ewy gap fall japan hedge equity dxj post gap oil gold play rally west texas intermediate crude price surge nearly barrel unite state oil uso vaneck vector oil service oih gap leap nearly powersharesdb oil dbo add gold future rise ounce investor seek safe haven vaneck vector junior gold miner gdxj vaneck vector gold miner gdx rise respectively spdr gold share gld ishare gold trust iau powershare db gold dbo gain more apiece financial chip biotechs lead downside spdr regional banking kre spdr bank kbe lose nearly recent stock market pullback continue create new opportunity investor buy equity first trust equity opportunity fpx be featured aug etf column moved closer day move average line solid rebound support line have set chance buy fall day few time next week then not only make lose ground have come back score time high market have rebound shape right side flat base fpx clear friday slip entry tuesday market sell etf gain late april flat base start most recent pattern fund track ipox index be launch april ipox be market cap weight index largest most liquid initial public offering put weighting cap component stock be reconstitute quarterly basis biggest sector weighting aug be technology health care consumer cyclical financial service accord morningstar direct top holding include abbvie abbv kraft heinz khc paypal pypl fpx have outperformed broader market ytd gain aug vs return year performance also outpace benchmark index average annual etf bear expense ratio ishare russell midcap growth iwp climb past flat base buy point intraday friday close just entry fund be highlighted july etf column near flat base buy point clear entry next session turn south broader market late july year old fund have amassed technology account asset aug industrial consumer cyclical health care top holding drugmaker zoetis zts chipmaker analog device adi gene sequence system maker illumina ilmn iwp ytd year average annual return respectively be ahead period fund expense ratio be thursday pick vanguard growth vug ishare russell growth iwf manage slight gain ahead labor day holiday vug be cusp flat base buy point iwf be still buy range past flat base entry learn more invest check page related biotechs extend gain breakout put apple amazon focusthese sector lead upside market beater close buy pointgold rally stock fall be too late buy gold
89,ZTS,here investing action plan tuesday need know investor come day xdisney earning be highlight quarterly report week big medium top rate online travel site priceline pcln weigh other highly rate company be also due tuesday monster beverage mnst
90,ZTS,generic drug giant mylan deliver mixed first quarter report late tuesday other top rate medical stock issue more positive report earlier day share slip fraction hour trading mylan myl profit rise year earlier quarter cent share beating analyst consensus penny accord thomson reuter sale increase
91,ZTS,stock rebound confidently wednesday index erase part previous session loss nasdaq jump dow jone industrial average skip higher tune respectively small cap russell gain volume stock market today run higher nasdaq lower nyse accord preliminary datum
92,ZTS,blue chip rally dozen stock stock dow gain more microsoft msft intel intc lead gain respectively microsoft intel have so so fundamental
93,ZTS,top rate stock also show strength breakout include chip designer technology avgo drug developer abbvie abbv
94,ZTS,new high top rate stock include bank ozark ozrk chip designer ambarella amba nxp semiconductor nxpi silicon motion technology simo hospital chain universal health service uhs drugmaker zoetis zts aerospace play spirit aerosystem spr tv station chain gray television gtn pizza restaurant papa john international pzza
95,ZTS,other leader show positive action retailer ulta beauty ulta retook day line strong volume illumina ilmn climb close buy point consolidation
96,ZTS,overall abundance top stock show good action be encourage development stock market uptrend
97,ZTS,company report quarterly result include apparel marketer michael kor kor gap earning miss weak outlook homebuilder toll bro tol skid revenue miss combine earning beat
98,ZTS,follow paul whitfield twitter ibd_pwhitfield stock rebound confidently wednesday index erase part previous session loss nasdaq jump dow jone industrial average skip higher tune respectively small cap russell gain volume stock market today run higher nasdaq lower nyse accord preliminary datum blue chip rally dozen stock stock dow gain more microsoft msft intel intc lead gain respectively microsoft intel have so so fundamental top rate stock also show strength breakout include chip designer technology avgo drug developer abbvie abbv new high top rate stock include bank ozark ozrk chip designer ambarella amba nxp semiconductor nxpi silicon motion technology simo hospital chain universal health service uhs drugmaker zoetis zts aerospace play spirit aerosystem spr tv station chain gray television gtn pizza restaurant papa john international pzza other leader show positive action retailer ulta beauty ulta retook day line strong volume illumina ilmn climb close buy point consolidation overall abundance top stock show good action be encourage development stock market uptrend company report quarterly result include apparel marketer michael kor kor gap earning miss weak outlook homebuilder toll bro tol skid revenue miss combine earning beat follow paul whitfield twitter ibd_pwhitfield
99,ZTS,core stock mutual fund invest growth value stock have be value fund little sister much past year trail performance core fund have catch thank surge growth component recent year average core mutual fund have turn investment dec
100,ZTS,relative strength rs rating astrazeneca azn enter higher percentile friday get lift ibd proprietary rs rating identify technical performance used worst best score show stock price performance trail week compare rest market history reveal stock go make biggest gain often have rs rating north early stage move see astrazeneca continue rebound clear threshold see ibd help make more money be buy range clear buy point consolidation once stock move higher original entry consider extend buy range earning growth fall most recent report revenue gain moved higher next quarterly number be expect feb astrazeneca hold rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
101,ZTS,get ready earning season focus stock potential buy range ahead next quarterly report abbvie abbv currently fit bill company be expect report jan trading buy point second stage flat base keep mind risky buy stock just report minimize exposure wait see company report market react see ibd help make more money stocksabbvie see earning sale growth rise last quarter earning share increase revenue rise consensus analyst estimate call earning growth quarter growth full year annual growth estimate be recently revise lower abbvie have composite rating hold rank peer medical ethical drug industry group zoetis zts grifol grfs be also group highest rate stock note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earningsbiotech pharmaceutical industry stock news
102,ZTS,horizon pharma hznp have relative strength rs rating upgrade friday proprietary rating identify technical performance used worst best score identify stock price action last week match other stock year market history reveal best stock tend have higher rs rating early stage move look best stock buy watch start herewhile stock be not proper entry right now see go form break proper chart pattern earning growth decrease prior quarter revenue grow previous report company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
103,ZTS,horizon pharma hznp see positive improvement relative strength rs rating thursday increase ibd proprietary rating identify market leadership worst best score score show stock price movement last week stack other stock database year market history reveal market biggest winner often have higher rs rating early stage move see horizon pharma continue show renew price strength clear threshold look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock go form base break earning growth fall most recent quarter sale moved higher company earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
104,ZTS,household appliance maker middleby midd be handful lead stock clear buy point hit new high wednesday even market wobble middleby make appliance brand include middleby marshall toastmaster vike rise clear flat base buy point volume be double average daily
105,ZTS,stock be quietly mixed early afternoon trading wednesday greece start talk eurozone finance minister debt compromise
106,ZTS,nasdaq picked dow jone industrial average lose nyse nasdaq volume be tracking very close tuesday level
107,ZTS,stock market today animal health care company zoetis zts pop strong result clear flat base buy point
108,ZTS,meanwhile pacira pharmaceutical pcrx extend gain recent cup shape base share add now buy point fourth quarter result be due feb open lead product exparel opioid pain medication be launch april
109,ZTS,apple aapl jump time high rise nearly tuesday apple pledge buy power first solar fslr california flat solar project monterey calif
110,ZTS,tesla motor tsla give day move average fall ahead earning report close luxury electric car maker be expect earn cent share year sluggish sale china overall sale be see rise accord yahoo finance
111,ZTS,acadium healthcare achc also report close quarterly profit be see rise cent share acadium operate inpatient psychiatric facility residential treatment center group home substance abuse facility share fall stock be quietly mixed early afternoon trading wednesday greece start talk eurozone finance minister debt compromise nasdaq picked dow jone industrial average lose nyse nasdaq volume be tracking very close tuesday level stock market today animal health care company zoetis zts pop strong result clear flat base buy point meanwhile pacira pharmaceutical pcrx extend gain recent cup shape base share add now buy point fourth quarter result be due feb open lead product exparel opioid pain medication be launch april apple aapl jump time high rise nearly tuesday apple pledge buy power first solar fslr california flat solar project monterey calif tesla motor tsla give day move average fall ahead earning report close luxury electric car maker be expect earn cent share year sluggish sale china overall sale be see rise accord yahoo finance acadium healthcare achc also report close quarterly profit be see rise cent share acadium operate inpatient psychiatric facility residential treatment center group home substance abuse facility share fall
112,ZTS,major average score big gain higher volume thursday european central bank announce plan increase asset purchase program still actionable chart today weekly review screen lead stock ibd industry group aren exactly plentiful course be exception medical ethical drug group volume have dry zoetis zts recent
113,ZTS,good news growth investor be market be back confirm uptrend even better news be week weekly review screen show plenty compelling candidate nagging distribution day nasdaq growth landscape be look better earlier week name zoetis zts middleby midd clear
114,ZTS,jazz pharmaceutical jazz have relative strength rs rating upgrade friday welcome improvement still short higher score prefer see proprietary rating track technical performance show stock price movement last week compare other stock database history reveal stock go make biggest gain tend have rs rating early stage move see jazz pharmaceutical continue rebound hit benchmark jazz pharmaceutical be work flat base buy point see stock break heavy trading earning growth rise company most recent report top line fall keep eye company next round number aug jazz pharmaceutical hold rank peer medical ethical drug industry group zoetis zts phibro animal health pahc be also group highest rate stock related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
115,ZTS,election republican president house congress trigger trump bump stock especially benefit corporate tax reform financial industry deregulation infrastructure spending be month karen hiatt lead manager allianzgi focuse growth fund pgwax be already hedge bet base policy initiative well fund usual fundamental criterium be accurate hiatt say portfolio benefit pass legislative initiative give result lift earning growth several holding outperformance be not reliant area fund be look more opportunity be consumer discretionary technology sector goal be uncover stock earning growth exceed market be find more interesting idea consumer discretionary tech fulfill goal say individual investor fund shareholder benefit insight fund move fund average annual gain year go wednesday top well fund large cap growth rival track morningstar inc large cap growth fund group averaged yearly gain mgm resort international mgm be consumer discretionary stock fund start current stake february have enlarged position then key attraction hiatt co manager raphael edelman be expect surge mgm revenue cotai casino open macau forecast second half year mgm have also be selling property lease back asset manager mgm growth property mgp arrangement let mgm resort focus core strength retain revenue property hiatt say fund boost stake amazon com amzn have increase position then trimming commerce titan earning share have slow straight quarters slumping first quarter hiatt see problem decline earning stem amazon investment various business amazon story be really revenue opportunity create say have see market share shift amazon away other retailer ve see success web service be very high margin be reason stock have climb ep growth slowdown investor give pass term earning growth know have investment be necessary future growth hiatt say apply material amat be name fund have be build position ep have grow triple digit pace quarters row company have benefit several trend say have benefit increase complexity semiconductor manufacturing benefit leadership role oled technology organic light emit diode technology demand have rise additional driver be internet thing ongoing rise big datum proliferation smartphone social medium require more semiconductor hiatt say so apply material not only have earning upside also valuation upside market have not yet appreciate add ibd take apply material average ep growth be past quarters check more apply fundamental technical strength ibd easy use stock checkup tool broadcom avgo be yet stock fund have build stake broadcom fit thesis consolidation semiconductor space have also diversify exposure semiconductor acquire other chipmaker hiatt say technology acquire broadcom keep latter name key takeover last year be brocade communication system hiatt say acquire company divest one don fit model then leverage own distribution drive synergy remain business other sector animal medicine maker zoetis zts be relative newcomer portfolio have ramp stake stock be animal health business be spun pfizer hiatt say give zoetis opportunity focus innovation create value believe happen here company have high corporate tax rate so corporate tax reform come congress be add bonus hiatt say related allianzgi fund bet regional bank be pay offwhat stock market do now find track best mutual fund
116,ZTS,tech stock highlighted monday action stock market today apple aapl retook buy point nvidia nvda hit new high dow jone industrial average be track straight xpowershare qqq trust qqq rise spdr dow jone industrial average dium spdr spy hold gain chip lead upside sector fund vaneck vector semiconductor smh ishare phlx semiconductor soxx more apiece component stock graphic chipmaker nvidia rally more new high soxx have form cup handle potential buy point consumer staple biotech retail also advanced oil play slide west texas intermediate crude price fall barrel vaneck vector oil service oih spdr oil gas exploration production xop be unite state oil fund uso dip powershare db oil fund dbo be flat energy bank most gold play also lag midcap exchange trade fund be buy zone test day move average line vanguard mid cap etf vo find support pull back july intraday peak prior bounce day early last month yielded gain year old fund track crsp mid cap index have amassed asset biggest sector weighting june be consumer cyclical nearly technology financial service industrial accord morningstar inc top holding include fiserv fisv newell brand nwl western digital wdc index be market cap weight individual stock position tend be more top holding account less asset many other index provider crsp rank stock market cap then build index base set percentage instance top market be consider mega cap next make crsp midcap universe also minimize turnover allow holding be share index so company shift market cap be moved next index stage instead once vo have trail year gain vs benchmark index aug slightly outpace past year past year return vs market cap weight index usually lead lower turnover vo annual turnover be expense ratio be ultra low ishare russell mid cap iwr featured column also find support day line etf stage june manage small advance pull back day early july fund marked anniversary last month have attract track russell midcap index also market cap weight also have low annual turnover iwr carry expense ratio prologis pld zoetis zts fidelity national information service fis be top holding account just total asset iwr also lag ytd basis gain pull ahead benchmark index past year past year thursday pick first trust equity opportunity fpx ishare edge msci quality factor qual have find support respective day line related sector gainer loser equity play buy etfs watch own nvidia top hold dow hold oil reverse higher big dividend play
117,ZTS,wake weak earning report teva pharmaceutical teva have long road ahead rival mylan myl prepare launch copycat teva copaxone drug generic environment worsen analyst say thursday xby close bell stock market today teva dove year low share collapse finish earlier crash much stock hit lowest point decade touch low last see quarter teva report sale line consensus adjust earning share lag average view analyst poll zack investment research topple year year biggest source pain come teva generic unit plunge generic drug sale fall european sale increase sale remainder world decline counter sale decrease president donald trump have say install competitive system bring drug price end food drug administration commissioner scott gottlieb have pledge speed generic approval lower drug cost ibd take teva isn only drugmaker struggle third quarter dow pfizer fall week low several drug legacy medicine unit lose market exclusivity head income investor more befall pfizer quarter teva acknowledge decline be mainly due challenge market dynamic include pricing decline result customer consolidation larger buy group accelerate fda approval generic version compete patent medicine specialty medicine also decline sale fall partially offset increase europe rest world respectively unit bring total sale quarter teva say news release biggest decline teva be azilect parkinson disease drug copaxone multiple sclerosis medication azilect topple copaxone teva largest moneymaker plunge fda approve generic version drug respiratory drug climb collective sale oncology drug inched teva cut forecast cite earlier generic competition multiple sclerosis drug copaxone teva now see adjust profit share vs prior guidance full year revenue be compare previous guidance analyst have previously call adjust income sale fourth quarter new guidance imply sale cent adjust earning share metric lag consensus expectation revenue adjust income share evercore analyst umer raffat sum teva quarterly report guidance cut sentence be long road ahead teva animal health specialist zoetis climb close top analyst view sale adjust income third quarter zoetis wrapped period adjust profit cent share revenue expectation cent respectively sale grow adjust profit rise vs year earlier quarter firm also raise full year target see adjust earning share sale analyst have modeled adjust profit share revenue related blood disease datum send biotech stock exelixis juno stock rocket crush viewsmylan topple president name mind blow antitrust scheme
118,ZTS,coherus bioscience chrs stock rocket month high wednesday board tossed key patent protect abbvie abbv most important drug arthritis medication humira thus clear obstacle similar treatment coherus late tuesday patent trial appeal board rule abbvie patent review invalidate dose patent humira rheumatoid arthritis increase chance launch coherus be know biosimilar generic biosimilar be intend be cheaper alternative patented drug be produce used live material rather chemical small cap biotech coherus biotech amgen amgn be work copycat abbvie top moneymaker humira be approve food drug administration treat rheumatoid arthritis psoriatic arthritis plaque psoriasis crohn disease arthritis affect spine do not mean coherus amgen anyone launch tomorrow do trigger process be likely result launch least year possibly year earlier consensus expect leerink analyst geoffrey porge say still porge keep market perform rating price target abbvie stock close stock market today coherus be month high abbvie stock fall ibd take abbvie stock have ibd composite rating meaning be outperform nearly stock term key growth metric still trail zoetis zts stock cr best possible head ibd stock checkup latest humira bring sale accounting abbvie total revenue last year patent protect humira composition matter expire so patent invalidate tuesday be see main obstacle biosimilar biosimilar now use same weekly milligram injection technique abbvie used humira infringe abbvie patent abbvie also have prevailed protect formulation patent set expire be upheld biosimilar need try work raffat write note client knowledge coherus have be very public intent do so meanwhile abbvie be also fend patent battle amgen amgen biosimilar amjevita be approve september amgen have say win launch litigation district court trial date have be schedule fall technically just act go district court appeal court drag time frame raffat say credit suisse analyst alethia young say decision be simply positive coherus negative abbvie note coherus be also work copy amgen bone marrow stimulant neulasta young question abbvie pipeline be robust enough offset decline humira sale evercore raffat note abbvie be enter very datum rich period pipeline related vertex big winner biopharma abbvie astrazeneca dip
119,ZTS,major index rise mixed close thursday successful health care reform vote congress outweighed negative effect sharp dive oil price nasdaq rebound midsession lows grasp fractional gain close bell dow jone industrial average fought good fight also rise lows end thinnest loss small cap lag russell end vote house representative moved gop health care reform bill american health care act senate move congress closer pledge repeal affordable care act oil price clearly hinder session west texas intermediate crude drop nearly barrel lowest price nov oil related stock post widest loss oil related industry post session worst loss caterpillar cat have high correlation oil price tumble bottom dow industrial follow closely chevron cvx exxon mobil xom decline stock pound big gain earning railcar america rail spiked air transport service group atsg soar fitbit fit rise fiber optic communication gear maker lumentum holding lite notch gain regeneron phamaceutical regn be top dog stock spring report mixed result robust sale eyelea treatment macular degeneration cheer investor send stock less buy point flat base aggressive investor have chart alternative buy point animal health drugmaker zoetis zts claw gain deliver first quarter result analyst target move retook buy point month flat base share end extend buy point new high ferrari race ahead stretch new high extend rebound week line april downside avon product avp crumble steel producer ryerson hold ryi collapse facebook fb post mild loss report stronger expect earning sale growth first quarter jeffery lift stock price target follow late wednesday report share remain extend april rebound week move average tesla tsla drop erase stock gain flat base buy point receive price upgrade jpmorgan brokerage continue be cautious stock give market weight rating related top stock buy zone investing action planfitbit pulse race beat much still prove
120,ZTS,mainstay large cap growth fund be roll portfolio be month end go tuesday be fund large cap growth rival track morningstar inc averaged gain mainstay mutual fund recent gain top own relative performance past
121,ZTS,merger mania be heating again ethical drug firm rush acquire other expand portfolio salix pharmaceutical slxp be target latest potential bidding war stock surge heavy trade feb report valeant pharmaceutical vrx be talk buy drug maker rise thursday
122,ZTS,equity etfs be essentially basket stock tend trade individual stock be less volatile be many other holding today pick be top respective flat basis prefer buy etf bounce day move average fund be also striking distance recent rebound xvanguard growth vug close monday just shy flat base buy point find support day line last week be support line share advanced nearly prior touch day line june intraday high fund track crsp large cap growth index have attract north asset technology be biggest chunk asset almost june follow consumer cyclical health care accord morningstar inc consumer defensive industrial make tech heavy stance be evident top holding apple aapl amazon com amzn facebook fb alphabet class googl class goog share name account nearly fifth total asset stock have rally more year vug have outperformed year date july slightly outpaced benchmark index base year average annual return year period etf return average annual vs vug carry expense ratio also close flat base entry recent bounce day line be ishare russell mid cap growth iwp fund advanced nearly late april flat base start current pattern fund celebrate anniversary monday provide exposure domestic midsize company be expect grow earning average pace vs market top holding july include drugmaker zoetis zts chipmaker analog device adi illumina ilmn maker gene sequence system technology be also biggest sector weighting fund asset iwp year average annual return be ahead gain have expense ratio monday emerge market pick be little change ishare emerge market dividend dvye remain just flat base buy point spdr emerge market dividend ediv be still buy range flat base entry related outsize dividend check hot emerge market playslook outside top dividend fund so far yearcan bull keep run second half expert weigh
123,ZTS,xbiotech stock clovis oncology clvs soar monday strong trial result ovarian cancer drug rubraca meanwhile big pharma stock abbvie abbv moved recent buy zone have relative strength rs rating upgrade year market history reveal stock go make biggest gain typically have rs rating north launch biggest climb see abbvie continue show renew price strength clear threshold abbvie have moved more past entry first stage flat base meaning now proper buy range look stock offer new chance get week tight pullback day week line company see earning sale growth rise last quarter earning share increase revenue rise abbvie earn rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz be also group highest rate stock related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
124,ZTS,bristol myer squibb bmy immuno oncology drug opdivo show promise early trial patient advanced cervical cancer drugmaker say friday american society clinical oncology conference chicago woman cervical vaginal vulvar cancer see reduction size tumor median progression free survival be month disease be controlled nearly patient partial complete response be only see cervical cancer patient respond treatment opdivo cancer type test opdivo present severe life threaten adverse response patient cancer test study be link human papillomavirus be tie cervical cancer vaginal cancer vulvar cancer bristol say news release hpv be spread sexual contact close bell stock market today bristol stock be ibd take bristol myer stock have ibd composite rating meaning outperform nearly third stock term key growth metric still lag drug leader zoetis zts have cr best possible head ibd stock checkup list top rate drugmaker first assessment opdivo activity woman advanced cervical vaginal vulvar cancer enrolled cohort study support further investigation especially patient have very limit option chemotherapy radiation fail say dr cheng statement typically patient type cancer be first treat chemotherapy alone combine radiation first year survival rate advanced cervical cancer be roughly stage patient stage patient bristol say earlier week bristol announce partnership small cap biotech advaxis adxs combination trial patient advanced cervical cancer opdivo be combine advaxis drug adxs dual immuno oncology drug related dow component merck beat rival bristol melanoma biotechs fall cancer partnership bristol myersbristol incyte match beat dow merck combination trial
125,ZTS,market uptrend have be pressure resume full strength tuesday thank strong percentage gain nasdaq higher volume tuesday sign strength do not mark follow day definition be enough prompt shift outlook market pulse right argue market be
126,ZTS,drug industry rumor mill get fresh surge energy wednesday report emerge drug giant actavis act be near deal buy botox maker allergan agn least report company be talk have be leak couple month now subject be major unnamed topic
127,ZTS,animal health giant zoetis zts offer guidance street consensus longer term financial goal analyst day tuesday brief halt trading early afternoon announcement stock be more afternoon trading stock market today zoetis say expect ep next year
128,ZTS,rest drugmaker be run cover zoetis zts lead animal health company be head new high zoetis develop animal health medicine vaccine focus livestock companion animal medical ethical drug industry group zoetis rank composite rating score composite rating combine
129,ZTS,pfizer pfe stock pop thursday report drugmaker be consider selling consumer care business less month firm opted long rumore corporate breakup evercore analyst john scottus expect potential transaction garner cent earning share midpoint forecast assume tax proceed sale be used share buyback potential sale make sense scottus write research report thursday pfizer reassess future pfizer walk away merger ireland base allergan agn april lawmaker look crack tax inversion deal company be set headquarters lower tax region such ireland pfizer also have long mulled corporate breakup splitting innovative essential health division scrap idea september johnson johnson jnj buy pfizer then consumer care business pfizer build unit back acquisition wyeth later pfizer sell nutrition business nestle spun animal health business zoetis zts thus sale current portfolio consumer product appear be logical next step allow pfizer focus core competency develop selling innovative drug scottus write ibd take trump presidency affect drug biotech stock get full skinny ibd industry theme reuter first report potential customer care sale late wednesday cite anonymous source unit pull sale annually scottus liken bayer acquisition merck mrk consumer care business annual unit stock market today pfizer stock climb day line ramp second consecutive day follow election president elect donald trump share rise wednesday drug biotech stock have rebound trump election trump be see less likely challenge drug price vs democrat hillary clinton unveil plan last year cut spiraling price tag drug trump have promise tackle affordable care act obamacare investment bank rbc say tuesday cause dip biotech stock uncertainty new not yet outlined national health care editor note correct fourth graph show zoetis be spinoff related pfizer likely overpay post allergan breakup flop twist pfizer scraps breakup follow dead allergan merger
130,ZTS,eli lilly lly aim take bite animal health market buy unit germany boehringer ingelheim be acquire sanofi sny animal health business zoetis zts spun pfizer pfe be animal health company boehringer likely become evercore isi analyst john scottus say email client wednesday lilly elanco unit get bigger lilly stock rise fraction stock market today zoetis stock fall fraction zoetis stock have be form flat base possible buy point lilly agree pay boehringer vermedica unit include common vaccine dog cat other animal well iowa manufacturing site include common vaccine bordetella parvovirus rabies zoetis sell rabies other vaccine cat dog scottus say speak lilly representative say boehringer vaccine portfolio deal expect close early next year generate annual revenue elanco total sale elanco account lilly revenue lilly buy animal health division novartis nvs early scottus say lilly indicated maintain operate profit margin target high last year say zoetis have target operate margin currently couple robust food animal portfolio addition further strengthen elanco position global animal health business lilly ceo john lechleiter say company press release boehringer say june sell vermedica unit antitrust regulator review acquisition sanofi animal health business ibd take lilly zoetis be ibd company medical ethical drug group rank just group track still group zoetis ty depome highest composite rating cr be broad measure performance look key metric such earning sale growth be good general target company cr rating related zoetis company radar janus fund managerslilly upgrade potential alzheimer drug
131,ZTS,go flow be well good rise head shoulder crowd be sign solid stock
132,ZTS,today screen day feature company have bolt relative strength line rs line track stock be do incline instance mean company be outperform index
133,ZTS,china base flash sale site vipshop holding vip report earning tuesday be expect report round triple digit earning revenue gain analyst poll thomson reuter see revenue surge ep bump cent share item
134,ZTS,security research firm capital say monday company seem be benefit current chilly weather china share have almost triple start calendar year
135,ZTS,fellow chinese tailer jumei international jmei report wednesday
136,ZTS,chinese search engine baidu bidu recently joined force beij base commerce company lightinthebox litb sell latter product apps lightinthebox retail bargain clothe home good electronic other product online mostly consumer outside china partnership give baidu leg try match pace heavyweight recent ipo alibaba group baba have team costco wholesale cost alibaba conduct wildly successful single day tail holiday last week
137,ZTS,veterinary drugmaker zoetis zts say monday acquire abbott laboratory animal health asset deal worth abbott animal health boost zoetis companion animal product portfolio expand diagnostic business say zoetis release
138,ZTS,small cap stock be spun pfizer pfe be mutual fund manager favorite bill ackman persh square last week disclose stake zoetis
139,ZTS,idexx laboratory idxx pet livestock health care company recently clear stock buy point
140,ZTS,company report result late october share earning rise share top cent sale grow beating analyst forecast
141,ZTS,related
142,ZTS,invest relative strength line confirm power go flow be well good rise head shoulder crowd be sign solid stock today screen day feature company have bolt relative strength line rs line track stock be do incline instance mean company be outperform index china base flash sale site vipshop holding vip report earning tuesday be expect report round triple digit earning revenue gain analyst poll thomson reuter see revenue surge ep bump cent share item security research firm capital say monday company seem be benefit current chilly weather china share have almost triple start calendar year fellow chinese tailer jumei international jmei report wednesday chinese search engine baidu bidu recently joined force beij base commerce company lightinthebox litb sell latter product apps lightinthebox retail bargain clothe home good electronic other product online mostly consumer outside china partnership give baidu leg try match pace heavyweight recent ipo alibaba group baba have team costco wholesale cost alibaba conduct wildly successful single day tail holiday last week veterinary drugmaker zoetis zts say monday acquire abbott laboratory animal health asset deal worth abbott animal health boost zoetis companion animal product portfolio expand diagnostic business say zoetis release small cap stock be spun pfizer pfe be mutual fund manager favorite bill ackman persh square last week disclose stake zoetis idexx laboratory idxx pet livestock health care company recently clear stock buy point company report result late october share earning rise share top cent sale grow beating analyst forecast related invest relative strength line confirm power
143,ZTS,april expert diagnosed virus spread quickly america pig have kill more piglet state early summer leadership team animal health company zoetis zts decide develop vaccine porcine epidemic diarrhea virus pedv company chief executive juan ramon alaix declare zoetis
144,ZTS,think sizzling new stock alibaba baba pole vault mind
145,ZTS,etf investor win find chinese commerce behemoth most broad base product so most likely miss alibaba gain door bust ipo new york just month
146,ZTS,broad mainstream index tend be conservative be slow include debut stock say kathleen principal renaissance capital ipo research investment management firm
147,ZTS,ipo etfs aim fix sluggishness renaissance ipo ipo snap largest most liquid newly list company little day initial trading quarterly review
148,ZTS,handful etfs now have stake alibaba top hold ipo well kraneshare csi china internet kweb weighting first trust ipo fpx allocate stock top hold
149,ZTS,re disruptor sort say company ipo etfs be grow faster overall economy
150,ZTS,investor seem shot outperform core broad base portfolio more seasoned stock year launch ipo have gather asset fpx seem gather dust first year existence zoetis zts debut begin potent string highflying ipos fpx asset have balloon roughly
151,ZTS,etfs be ideal way capture return security aren include be underinclude core portfolio expert say
152,ZTS,diversify less risky approach pick next hot ipo stock stock basis say ryan issakainen etf strategist first trust advisor
153,ZTS,high profile name
154,ZTS,more half recent ipos be red first year average return tend beat broader stock market add etfs allow get exposure average performance issakainen say
155,ZTS,so far fpx have rise strength abbvie abbv facebook fb hca holding hca alibaba tesla tsla account portfolio combine return lag spdr spy year average annual year average beat average annual period
156,ZTS,tesla terrific performer last few year be not even large cap issakainen note marsh mclennan mmc be
157,ZTS,investor have take note fpx recent track record uptick demand financial adviser lead debut first trust international ipo fpxi november issakainen say renaissance launch own international ipo ipos october fpxi ipos have rake respectively then
158,ZTS,more ipo etfs wing renaissance have regulatory approval product tracking ipo market asia pacific region europe consumer technology sector plan launch soon
159,ZTS,stoyan bojinov analyst etf database advise investor study methodology different ipo etfs be aware nuance say note fpx keep holding year ipo hold year
160,ZTS,accord renaissance company have come public so far last year amount ipos raise investor rise average ipos gain offer price so far year company have file ipo think sizzling new stock alibaba baba pole vault mind etf investor win find chinese commerce behemoth most broad base product so most likely miss alibaba gain door bust ipo new york just month broad mainstream index tend be conservative be slow include debut stock say kathleen principal renaissance capital ipo research investment management firm ipo etfs aim fix sluggishness renaissance ipo ipo snap largest most liquid newly list company little day initial trading quarterly review handful etfs now have stake alibaba top hold ipo well kraneshare csi china internet kweb weighting first trust ipo fpx allocate stock top hold re disruptor sort say company ipo etfs be grow faster overall economy investor seem shot outperform core broad base portfolio more seasoned stock year launch ipo have gather asset fpx seem gather dust first year existence zoetis zts debut begin potent string highflying ipos fpx asset have balloon roughly etfs be ideal way capture return security aren include be underinclude core portfolio expert say diversify less risky approach pick next hot ipo stock stock basis say ryan issakainen etf strategist first trust advisor high profile namesalthough more half recent ipos be red first year average return tend beat broader stock market add etfs allow get exposure average performance issakainen say so far fpx have rise strength abbvie abbv facebook fb hca holding hca alibaba tesla tsla account portfolio combine return lag spdr spy year average annual year average beat average annual period tesla terrific performer last few year be not even large cap issakainen note marsh mclennan mmc be investor have take note fpx recent track record uptick demand financial adviser lead debut first trust international ipo fpxi november issakainen say renaissance launch own international ipo ipos october fpxi ipos have rake respectively then more ipo etfs wing renaissance have regulatory approval product tracking ipo market asia pacific region europe consumer technology sector plan launch soon stoyan bojinov analyst etf database advise investor study methodology different ipo etfs be aware nuance say note fpx keep holding year ipo hold year accord renaissance company have come public so far last year amount ipos raise investor rise average ipos gain offer price so far year company have file ipo
161,ZTS,disappointing result type diabetes drug budureon lead pharmaceutical stock astrazeneca azn continue move higher last month rival nordisk nvo jump news thursday astrazeneca get upgrade relative strength rs rating clear higher score look decade market research show best stock often have rs rating north early stage move astrazeneca have moved more past entry first stage cup handle meaning now proper buy range look stock create new chance pick share week tight pullback day week move average earning share growth decrease company latest report sale growth show modest improvement edge right direction astrazeneca hold rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz grifol grfs be top highly rate stock group related nordisk diabetes lead unscathed follow astrazeneca trialbiotech pharma stock watch industry newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
162,ZTS,shire shpg stock launch month high thursday lead drug industry unveil strong phase result drug treat rare condition cause swell skin intraday stock market today shire stock be close earlier rise much touch high last achieve november ibd company medical ethical drug industry group sank collective trial dub help test shire drug lanadelumab patient hereditary angioedema genetic condition affect symptom include episode swell face extremity tract upper airway lanadelumab prove clinically meaningful meet goal trial shire say milligram dose administer week angioedema attack decrease average vs placebo dosage higher proportion patient vs placebo be attack free entire week study period study experience more attack month baseline have history laryngeal attack be long term treatment patient complete week study choose continue longer term safety study ibd take shire stock have ibd composite rating meaning outperform quarters stock term key growth metric still lag zoetis zts lead group cr visit ibd stock checkup list best rate stock rbc analyst dougla miehm note wall street be broadly expect strong result help study be risk datum not match generate phase trial such expect share see upside response news overall remove overhang shire stock miehm write note client keep outperform rating shire stock shire plan submit application food drug administration late early miehm expect shire launch drug second third quarter related incyte team dow merck trounce roche cancerbiogen spinoff downgrade mount roche shire rivalry
163,ZTS,astrazeneca azn have relative strength rs rating upgrade thursday proprietary rating measure market leadership show stock price movement last week measure action other stock database history show market biggest winner typically have higher rs rating early stage move astrazeneca have rise more past entry first stage cup handle meaning now proper buy zone look stock create new buy opportunity week tight pullback day week move average ep growth decline company most recent report sale show mild improvement company hold rank peer medical ethical drug industry group zoetis zts grifol grfs jazz pharmaceutical jazz be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
164,ZTS,ve ever search thousand stock trade wonder be just have trouble find good stock buy have fear be not alone money manager janus jdcax have chalk best performance gain multiple time period mutual fund limit holding stock reason don think be many great idea point time say lead manager dougla rao compare mutual fund own more stock janus also get know company own better say click here see list mutual fund month leaderstalk reason like gaming company activision blizzard atvi rao say invest owner operator manager act way think long term activision ceo bobby kotick be guy management team buy close company janus be ibd best mutual fund award winner have outperformed year period end dec only diversify stock fund meet standard click here see list mutual fund category performancetop perform holding year include boston scientific bsx facebook fb time warner wtx amazon amzn fund have lighten position boston facebook latest report period hold steady time warner increase amazon general electric ge top hold asset be flat year yielding hasn be janus best year fund be year aug vs have month performance rating ibd meaning share price performance be top mutual fund time rao have be board nick schommer become co manager year helmsman talk ibd approach current investing climate office ibd fund be concentrated do focus just best idea rao don think be many great idea point time take cue warren buffett call diversification di worsification say know idea better idea idea have more conviction be naturally comfortable level term have ability know company invest ibd do concentration entail greater risk volatility schommer wouldn say strongly help manage volatility hold different bucket growth stock ibd do stock bucket differ schommer percent portfolio be compound growth company be company well defined competitive moat have year growth ahead high earning visibility lower risk trade slight premium market have much better growth percent be blue sky company be growth company have less well defined competitive moat compound growth stock expect blue sky company solidify moat graduate compound growth company have big opportunity make position small manage risk third bucket hold special situation stock be future compound growth stock meanwhile be business issue financial leverage issue company have execute example ge past year have be divest ge capital business hasn be very attractive ge have be reinvest remain industrial nonfinancial business return capital shareholder key success blue sky special situation company be have graduate be compound growth company want ge ibd other key trait do stock bucket share rao start same filter do company have competitive advantage do believe be sustainable bucket stock be look same way ibd percent blue sky special situation company do graduate rao guess maybe ibd fund be top morningstar large cap growth category year more middle pack have year be more challenge schommer general market year reward lower volatility sector area lot growth sector naturally tend take pass investing sector be reward year be consumer staple utility energy tend be sector be not large position portfolio company meet business model hurdle not lot meet growth hurdle now particularly be not attractive valuation perspective market have treat income substitute give premium valuation due low yield fix income have instead focuse investment zoetis zts animal health care company have characteristic similar consumer staple company better growth prospect more reasonable start valuation energy be area have be good performer year difficult be limit number energy company meet business model criterium most be price taker tie commodity price ibd ve slightly trim stake facebook be concern rao hard talk talk google googl alphabet have become dominant platform advertising dollar shift traditional channel digital reason facebook have be so effective monetize digital advertising dollar be have high consumer usage property chief operate officer sheryl sandberg team leadership ceo mark zuckerberg have do good job pivot company away be desktop computer base be dominant app provider global basis outside china whatsapp instagram facebook consumer be engage such extent advertising dollar move ibd bucket be boston scientific rao compound growth buy maybe year start special situation have fairly significant legal overhang johnson johnson sue thought case be questionable bring new ceo name mike mahoney have be johnson johnson come reinvigorate cardiology franchise have miss product cycle feel be pipeline need be push market be concern litigation factor little growth cardiology product soon settle johnson johnson suit ve accelerate revenue growth margin growth have be half competitor ve close gap execution have be fantastic expect more ibd be activision blizzard position ve increase rao be special situation buy king digital have popular candy crush game market soured king go public ceo bobby kotick have make number strategic pivot king acquisition get mobile ve go be company serve consumer desktop console serve consumer person watch game play also ve transition more digital download dependence customer buy console remove middle man so activision margin become higher still special situation mobile user king acquisition have be shrink top see re engage consumer ibd amazon amzn have go size portfolio be rao have reduce exposure end last year have disappointing announcement january stock get punish add back sank dramatically amazon be dominant player commerce commerce percentage retail sale continue increase amazon continue deliver faster fulfillment time gain market share leg stool be amazon web service get idea investing owner operator many person see aw money pit fast forward today most analyst see worth microsoft be do nice job web service aw be dominant provider everyone cia ge be move more business aw don have have electricity plant house so do need own datum center ibd celgene celg be yet company ve build stake thesis rao reduce position middle last year then year go high mid analyst feel confident be trading big discount view intrinsic value ibd do trim priceline pcln stake slow global growth mean less travel rao be business benefit network effect core business be book com be hotel book europe have similar business asia call agoda reduce give exposure europe terrorist attack higher level management turnover be comfortable ibd ve also trim nxp semiconductor nxpi be concern schommer special situation be merger lead semiconductor company freescale nxp be end market give share profit line invest more competitor merger financial leverage business increase level be normalize operate level so part be special situation be re watch reduce balance sheet more comfortable level ibd adobe adbe be trim thesis rao be first transition selling software shrink wrap subscription model transition be much larger market transition revenue margin decline trim company have largely make transition subscription business market be now reward higher quality revenue related top fund manager like type growth stockswhat do fund get new managermutual fund award top equity fund
165,ZTS,share animal health giant zoetis zts rise month high early trading wednesday company beat estimate modestly raise guidance earning grow year earlier quarter beat analyst consensus sale rise top estimate zoetis pet care business do especially well growth help canine itch treatment apoquel well newly approve oral flea killer simparica international growth be more modest partly result company plan cutback operate efficiency livestock revenue be also strong cattle business start recover relatively weak performance be due mild winter lower demand zoetis product segment note evercore isi analyst mark schoenebaum email company add full year sale guidance now also add cent share ep range now mean just earning growth year slowdown previous year company have guide rebound outlook remain unchanged zoetis share rise stock market today ibd take zoetis move wednesday bring week high bullish sign ibd track new high list preferably be accompany high relative price strength rating zoetis have modest rs
166,ZTS,share valeant pharmaceutical international vrx be rise monday company continue fill new management lineup appoint new chief financial officer valeant nab paul herendeen animal health company zoetis zts have be executive vice president last year also be cfo number year warner chilcott buyout company eventually become allergan agn valeant current cfo robert rosiello become head corporate development strategy role cfo be crucial valeant recent accounting scandal result company restate last couple year earning rosiello wasn implicate trouble really happened june appointment previous cfo howard schiller take most heat valeant audit committee produce report march same time ceo michael pearson quit ibd take valeant become poster child drugmaker rely price increase goose revenue learn much other big cap drugmaker be rely price vs demand rbc capital market analyst dougla miehm write change be probably due match talent job view new role mr rosiello favorably work mckinsey year have advise company health care consumer product technology sector venture operational strategic initiative miehm write research note valeant stock rise stock market today just second day past month rise also have be fuel wider bounce drug stock view buyout target light pfizer pfe buyout medivation mdvn valeant earning call ceo joseph papa say be prepared sell worth asset wall street have wonder buyer acquire entire company now week high related
167,ZTS,drug stock pop collective midday thursday gop health care bill repeal replace major portion obamacare narrowly pass house follow vote ibd company medical ethical drug industry group rise month high generic drug biotech stock other hand advanced just apiece zoetis zts stock lift follow consensus crush first quarter earlier day also endo international endp stock rise mallinckrodt mnk stock pop eli lilly lly stock be analyst have say uncertainty regard president trump health care ambition weigh biotech pharma market year april leerink analyst geoffrey porge tell investor business daily doesn seem accumulate worry be go go away hurry re worry donald trump health care reform re worry fda reform now re worry drug pricing regulation say ibd take biotech stock be now rate group track head ibd stock checkup list top rate biotech stock house vote land largely partisan line president trump day office republican laud bill major current form eliminate individual coverage mandate protection patient pre exist condition trumpcare state be allow apply waiver exempt essential health benefit outlined obamacare include coverage maternity newborn care prescription drug mental health accord congressional budget office bill be expect reduce federal deficit average premium single policyholder be expect rise number uninsured grow related biotech surge survive volatile market
168,ZTS,nordisk nvo stock pop tuesday astrazeneca azn say type diabetes drug didn reduce risk cardiovascular event trial leave eli lilly lly break tie stock market today nordisk fall cent astrazeneca be share lilly diabetes rival be astrazeneca drug bydureon meet goal phase study do not increase risk major adverse cardiovascular event include heart attack stroke patient type diabetes meeting food drug administration requirement also didn reduce risk nordisk victoza semaglutide do earlier study victoza cut risk cardiovascular event semaglutide trim risk leerink analyst seamus fernandez write note client drug also have cardiovascular benefit evercore analyst umer raffat say note client so far astrazeneca bydureon sanofi sny adlyxin fail cut risk cardiovascular event nordisk drug have ibd take astrazeneca have ibd composite rating meaning have outperformed stock key growth metric past month still lag leader zoetis zts have cr best possible head ibd stock checkup list top rate drugmaker lilly provide tiebreaker unveil result trial diabetes drug trulicity drug astrazeneca nordisk sanofi trulicity belong class drug increase insulin secretion inhibit glucose release certain level fernandez forecast entire class drug grow worldwide sale meantime drug maintain leadership position class dub glp receptor agonist fernandez say class be underuse diabetes treatment positive heart effect astrazeneca trial have boost prominence lilly trulicity be gain share glp class say count once weekly semaglutide launch stem tide also benefit update label victoza reflect drug ability curb risk cardiovascular event diabetes patient related conference spotlight drug giant donnybrook cancer treatmentlilly grab diabetes share dow amputation woesdow pfizer eli lilly topple month lows downgrade
169,ZTS,mild rebound oil price do little stir stock wednesday index open narrowly lower dow industrial nasdaq dip open private employer add new worker july accord adp national employment report be new hire june easily outpace consensus projection dip hiring net gain include service sector position add good produce firm reduce payroll job researcher markit deliver july service purchasing manager index et et institute supply management report july service index energy information administration report weekly oil inventory quarterly report be key driver ahead wednesday open real earning firework be set start hour trade tesla motor tsla continental resource clr ebix ebix company plan report drug maker zoetis zts jump open follow strong second quarter report zoetis end tuesday buy point follow double bottom base time warner twx share tune nearly gain report mixed second quarter result company also say agree buy stake stream tv show provider hulu term be not disclose time warner share have climb february work way year long consolidation fitbit fit pull report late tuesday second quarter sale earning easily top analyst target gross margin come just forecast insurance industry flagship american international group aig muscle open new york base company report stronger forecast second quarter result raise share buyback program chipmaker qorvo qrvo tumble open greensboro base company report fiscal first quarter revenue earning beat expectation raise second quarter revenue guidance consensus view foreign automaker be motion fiat chrysler fcau nearly india tata motor ttm start bell oil future inched higher west texas intermediate crude almost still barrel wti be so far week benchmark track sixth loss past week brent crude edge just gold slip fractionally trade ounce dollar stage broad rebound bond also bounce send year treasury yield basis point overseas china market be mixed shanghai composite rise hong kong hang seng index fall reopen day storm shutdown tokyo nikkei stumble pressured rise yen europe market come moderate selling pressure early afternoon trade
170,ZTS,job report push stock fresh time high busy week tesla motor tsla announce deal buy solarcity scty tech be strong general motor gm ford fuel sell consumer related stock oil price briefly undercut barrel also bank england cut rate revive bond buy major average be little change thursday rally friday strong job report nasdaq climb week record close friday just point july intraday peak rise hit fresh intraday best dow jone industrial average advanced energy stock fall oil undercut early week rally crude re-cover somewhat economy add job july second straight month much better expect hire allay fear economy ism manufacturing index index fall little more forecast still point growth strong hire wage gain support consumer spending housing demand many consumer related firm report stall demand tesla take step closer acquire solarcity special committee independent disinterested solarcity board member evaluate proposal alternative state approval merger deal still need be approve shareholder regulator tesla report earning miss estimate show improvement electric car production production be track support delivery second half reaffirm previous guidance electric car company loss balloon share cent year earlier figure much greater cent loss estimate tesla report gaap revenue miss consensus tesla fall week solarcity lose more ride hail giant uber technology be selling chinese operation apple aapl backed rival didi chux technology capitulate expensive battle foothold china deal have uber swap chinese business stake didi make former foe largest stakeholder didi turn didi become facto ride hail leader china value more uber most recent valuation put north verizon communication vz agree buy fleetmatic fltx vehicle tracking system maker share acquisition expand verizon push web connect vehicle part internet thing ireland base fleetmatic mobile software platform let business manage commercial fleet provide datum vehicle location fuel usage speed mileage verizon fall week drop buy point day move average fleetmatic jump time warner twx st century fox foxa turn mixed result time warner move buy stake netflix nflx rival hulu join current co owner walt disney fox comcast cmcsa steal headline viacom viab report better expect earning revenue do lion gate lgf post surprise profit oil price fall barrel early week follow july tumble opec production climb strong output nigeria iraq saudi arabia continue pump oil record high crude stockpile rise latest week accord energy information administration production dip gasoline supply fall shale producer continental resource clr oasis petroleum oas laredo petroleum lpi lift output forecast oil close week higher bristol myer squibb bmy plunge friday cancer drug opdivo end string clinical trial success failure trial single therapy newly diagnosed lung cancer patient merck mrk have succeed similar patient group trial compete drug keytruda be aim smaller potential market merck stock jump hit highest level june earlier merck be report be talk biogen biib possible biogen buyout be allergan agn further boost biogen stock day partner ionis pharmaceutical ion announce unexpected success clinical trial nusinersen treatment rare spinal disease blockbuster potential biogen rise nearly week meanwhile specialty drugmaker mallinckrodt mnk shire shpg rise respectively beat estimate raise guidance pfizer pfe nordisk nvo regeneron pharmaceutical regn slip beat number issue so so guidance animal health company zoetis zts also rise beating raise general motor gm ford lead auto stock lower report slower sale month july ford project industry sale fall year big gain department store grocery store restaurant airline also decline re-cover somewhat week end sell consumer stock trigger warning broader economy fall business investment homebuilder spending consumer spending rise strong annual rate falter economy not be able match anemic gdp growth texas roadhouse txrh beat earning estimate ep cent revenue growth miss view steakhouse chain also say early same restaurant sale growth have slow outlook come grow worry restaurant sector overall starbucks sbux mcdonald recently report weak comp warning analyst retail sector pizza delivery chain include papa john pzza be buck trend papa john say ep jump cent top view raise guidance rest year also chicken theme el pollo wingstop wing rally result jack box jack soar earning separately monster beverage mnst report weaker expect earning growth top revenue forecast monster beverage leaderboard stock rally friday hit new high ibd take investor look growth stock clear proper buy point ibd leaderboard be premium service provide detailed chart analysis lead stock see other top rate growth name be buy point bank england cut interest rate quarter point expect economy slow reaction brexit vote policymaker go further revive government bond purchase announce boe buy corporate debt also signale rate cut be likely year end boe gov mark carney say opposed negative rate helicopter money martin marietta material mlm make crushed stone sand other aggregate used construction fall short second quarter forecast rival aggregate supplier vulcan material vmc also badly miss related ready mix concrete market concrete uscr report ep plunge cent miss cent revenue rise also miss blame bad weather say expect better result second half martin marietta ceo nye cite record record rainfall attendant effect many key market share trio fall hard earning miss re-cover lose ground end week delta air line dal report decrease passenger unit revenue july say drop be line expectation investor appear worry tone result set third quarter delta say key metric operate efficiency fall german carrier lufthansa warn terror attack economic uncertainty affect travel also hurt sector delta stock fall american airline aal jetblue jblu also sank unite airline ual southwest luv close week higher aetna aet humana hum wellcare wcg put estimate beating quarterly result week however aetna say abandon expansion plan obamacare exchange humana recently say exit most obamacare exchange market next year follow unitedhealth unh aetna humana try overcome antitrust objection merger safety security concern person mind wake series officer involved shooting polouse officer polouse unarmed civilian sale sturm ruger rgr firearm grow second quarter rise earning climb share fbi report firearm background check see indicator future gun sale rise july june be july share fall day earning ruger ceo say be step close week only meanwhile taser international tasr say ep fall cent share cent year beat forecast cent share sale pop easily top view stun gun maker say booking axon body camera soar taser stock rise hit year high
171,ZTS,vca massive west los angele animal hospital pet get chemotherapy mri scan receive acupuncture chinese herbal treatment rehab underwater treadmill be enter behavioral counsele well join weight management regimen dog cat rabbit bird prey potbelly pig welcome hospital offer high profile proof thrive pet health
172,ZTS,horizon pharma hznp offer expect sale guidance tuesday morning first second quarters send share gapping day line drugmaker deliver net sale guidance range indicate year year growth midpoint net sale outlook growth midpoint well current estimate revenue gain growth previous year management say earning call see have highest operate expense percentage sale year leverage build move year result lower adjust ebitda earning interest taxe depreciation amortization margin first quarter expect sequentially increase move year horizon also confirm full year sale guidance analyst poll thomson reuter anticipate revenue year share slide crash stock market today slice downward key move average stock have be trading day level september company be member ibd medical ethical drug industry group joined abbvie abbv pfizer pfe group leader zoetis zts abbvie share rise pfizer zoetis related egregious depome soar activist starboard target drugmaker
173,ZTS,animal health giant zoetis zts beat earning estimate trim revenue guidance tuesday company continue face foreign exchange headwind zoetis earning exclude time item rise cent share beating analyst consensus cent accord thomson reuter revenue shrank still consensus exclude foreign exchange impact
174,ZTS,market volatility rev high gear january make investor queasy up down stock end bust first month year back oil slump weak corporate earning nasdaq plunge january sank manager nation best perform fund past month have step brake slow stock buy just select few top rate stock have defy gravity household tech name such facebook fb alphabet googl verizon communication vz equinix eqix have see buy action lead fund latest report period click here see list new buy top mutual fundsa handful property reit such stor capital stor mid america apartment community maa sovran self storage sss be solid performer recent month also favore top perform fund finance property reit group be rank industry wednesday top fund also add defensive utility stock atmos energy ato pnm resource pnm itc hold itc american water work awk black hill bkh ibd spot lead fund buy edward lifescience ew investing estimate latest report period fidelity contrafund fcntx add share portfolio irvine calif base firm make market medical device treat heart disease edward report fourth quarter earning result cent share year earlier beating analyst estimate cent revenue rise fourth quarter earning growth be drive high demand sapien sapien xt heart valf be deliver procedure call transcatheter aortic valve replacement therapy tavr critical care product group include hemodynamic monitoring device also perform well globally fourth quarter edward stock hold steady most stock market sell january stock clear flat month base wednesday upbeat fourth quarter earning nation lead fund have be unload lilly eli co lly latest report period be net selling fund position other drugmaker zoetis zts baxalta bxlt be also slash click here top fund latest sell
175,ZTS,san francisco jpmorgan healthcare conference continue yield mixed result investor second day tuesday several company tweak guidance big pharmas offer incremental update specialty drugmaker horizon pharma hznp have best day share rise company update guidance ahead presentation wednesday horizon say
176,ZTS,analysis october sale im health im show sanofi sny be continue gain market share biogen biib multiple sclerosis accord rbc capital market biogen sell worth drug tecfidera october week analyst michael yee note be september
177,ZTS,animal health giant zoetis zts see share hit more month high tuesday beat wall street earning estimate announce acquisition fish medicine company late monday
178,ZTS,zoetis say earning rise year earlier quarter cent share exclude time item beating analyst consensus cent accord thomson reuter revenue be flat street average estimate exclude impact foreign exchange rate revenue rise
179,ZTS,zoetis raise full year ep guidance cent range lower top end sale guidance range be now also raise previously issue guidance next year ep range be few cent higher revenue higher previously company add sale guidance now ep few cent higher
180,ZTS,include guidance be zoetis acquisition pharmaq zoetis announce late monday price tag base norway pharmaq provide medicine mainly farm fish market zoetis say be grow year pharmaq pull just revenue last year zoetis executive tout growth opportunity
181,ZTS,be gain new platform growth value creation expand zoetis ceo juan ramon alaix say statement pharmaq strengthen core livestock business provide market leadership aquatic health strong late stage pipeline world largest category protein fastest grow animal health market
182,ZTS,tax rate shrink
183,ZTS,evercore isi analyst mark schoenebaum note guidance number also look good investor concern zoetis relatively high tax rate have lead shareholder pressure management move lower tax jurisdiction zoetis be headquarter florida park
184,ZTS,addition beat partially drive tax zts decrease fy tax rate guidance respectively be consensus schoenebaum write email client conference call management add reduce tax rate guidance reflect operate improvement be expect continue future year zoetis note long term tax rate improvement be evolutionary not revolutionary
185,ZTS,zoetis stock be almost late morning stock market today stock hit record high june rumor valeant pharmaceutical vrx be interested acquire scenario seem unlikely now give valeant current wo
186,ZTS,then zoetis share have decline rest medical ethical drug group even main driver decline political pressure lower drug price have nothing do animal health
187,ZTS,schoenebaum note come conference call management expressed disappointment recent performance zoetis stock reiterate recent concern regard sustainability drug pricing do not apply zoetis animal health pricing be market drive do not involve third party payer animal health industry be resilient change economic dynamic
188,ZTS,follow amy reeve twitter ibd_areeve facebook animal health giant zoetis zts see share hit more month high tuesday beat wall street earning estimate announce acquisition fish medicine company late monday zoetis say earning rise year earlier quarter cent share exclude time item beating analyst consensus cent accord thomson reuter revenue be flat street average estimate exclude impact foreign exchange rate revenue rise zoetis raise full year ep guidance cent range lower top end sale guidance range be now also raise previously issue guidance next year ep range be few cent higher revenue higher previously company add sale guidance now ep few cent higher include guidance be zoetis acquisition pharmaq zoetis announce late monday price tag base norway pharmaq provide medicine mainly farm fish market zoetis say be grow year pharmaq pull just revenue last year zoetis executive tout growth opportunity be gain new platform growth value creation expand zoetis ceo juan ramon alaix say statement pharmaq strengthen core livestock business provide market leadership aquatic health strong late stage pipeline world largest category protein fastest grow animal health market tax rate isi analyst mark schoenebaum note guidance number also look good investor concern zoetis relatively high tax rate have lead shareholder pressure management move lower tax jurisdiction zoetis be headquarter florida park addition beat partially drive tax zts decrease fy tax rate guidance respectively be consensus schoenebaum write email client conference call management add reduce tax rate guidance reflect operate improvement be expect continue future year zoetis note long term tax rate improvement be evolutionary not revolutionary zoetis stock be almost late morning stock market today stock hit record high june rumor valeant pharmaceutical vrx be interested acquire scenario seem unlikely now give valeant current wo then zoetis share have decline rest medical ethical drug group even main driver decline political pressure lower drug price have nothing do animal health schoenebaum note come conference call management expressed disappointment recent performance zoetis stock reiterate recent concern regard sustainability drug pricing do not apply zoetis animal health pricing be market drive do not involve third party payer animal health industry be resilient change economic dynamic follow amy reeve twitter ibd_areeve facebook
189,ZTS,stock future be mildly lower steady ahead tuesday open dow future trade point fair market value nasdaq future be point future backed point
190,ZTS,stock market today set nasdaq begin high nasdaq open year high marked july be high index be sit top week rally strongest run up october november rally last year
191,ZTS,light day economic news include october car sale number release automaker day commerce department report september factory order datum et
192,ZTS,oil trade less west texas intermediate hold barrel gold slip fraction just ounce
193,ZTS,stock king digital entertainment king maker addictive candy crush online game zoom premarket action video game heavyweight activision blizzard atvi agree buy ireland base king cash activision share monday close just oct high slip
194,ZTS,big name motion follow earning report include daniel adm sprint tech name fitbit fit taser international tasr be also sharply lower quarterly result
195,ZTS,discovery communication disca skip report mixed result earning top revenue miss analyst consensus estimate management also announce share buyback program stock have be weaken consolidation month
196,ZTS,zoetis zts report healthy beat jump florida park company top estimate sale earning line hoist full year ep guidance expectation stock have scoop deep consolidation begin june
197,ZTS,leader atlanta base payment processor global payment gpn jump bell stock end monday just last week high well extend buy point
198,ZTS,ryanair holding ryaay picked premarket gain ireland base economy airline be flat base buy point
199,ZTS,overseas market be mixed japan morning standout tokyo nikkei drop drag iron steel stock tumble weak manufacturing datum china stock future be mildly lower steady ahead tuesday open dow future trade point fair market value nasdaq future be point future backed point stock market today set nasdaq begin high nasdaq open year high marked july be high index be sit top week rally strongest run up october november rally last year light day economic news include october car sale number release automaker day commerce department report september factory order datum et oil trade less west texas intermediate hold barrel gold slip fraction just ounce stock king digital entertainment king maker addictive candy crush online game zoom premarket action video game heavyweight activision blizzard atvi agree buy ireland base king cash activision share monday close just oct high slip big name motion follow earning report include daniel adm sprint tech name fitbit fit taser international tasr be also sharply lower quarterly result discovery communication disca skip report mixed result earning top revenue miss analyst consensus estimate management also announce share buyback program stock have be weaken consolidation month zoetis zts report healthy beat jump florida park company top estimate sale earning line hoist full year ep guidance expectation stock have scoop deep consolidation begin june leader atlanta base payment processor global payment gpn jump bell stock end monday just last week high well extend buy point ryanair holding ryaay picked premarket gain ireland base economy airline be flat base buy point overseas market be mixed japan morning standout tokyo nikkei drop drag iron steel stock tumble weak manufacturing datum china
200,ZTS,facebook be highlighted column nov ibd daily price action be example whipsawing sell signal be stack flapjack late morning sunday breakfast point however stock price action world top social network have settle stock be rise comfortably day move average
201,ZTS,medical company dominate upper echelon stock weekly review pace maker drug medical product valeant pharmaceutical vrx jump nearly thursday canadian drugmaker post better expect gain profit revenue also rise beat analyst expectation
202,ZTS,volume be heavy stock clear buy point flat base en route new high
203,ZTS,valeant cite gain dermatology contact lens dental business company have be acquisition spree most recently announce plan buy amoun pharmaceutical egypt largest drugmaker help expand middle east africa valeant earlier year buy salix pharmaceutical have be rumore be interested animal medicine company zoetis zts
204,ZTS,zoetis be also weekly review report result aug
205,ZTS,profit period be see flat cent share decline sale
206,ZTS,zoetis be secondary buy range rebound week line
207,ZTS,valeant lead highly rate medical ethical drug industry best possible composite rating comprise key ibd metric zoetis rating be
208,ZTS,medical product group also highly rate be lead abiom abmd cambrex cbm enjoy top notch fundamental
209,ZTS,abiom maker heart pump be approach cup type base buy point
210,ZTS,report earning aug profit be see cent share vs loss cent year earlier quarter sale be expect jump
211,ZTS,cambrex help drug company develop process manufacture drug be nearly past buy point cup handle base level investor consider take profit many stock correct point medical company dominate upper echelon stock weekly review pace maker drug medical product valeant pharmaceutical vrx jump nearly thursday canadian drugmaker post better expect gain profit revenue also rise beat analyst expectation volume be heavy stock clear buy point flat base en route new high valeant cite gain dermatology contact lens dental business company have be acquisition spree most recently announce plan buy amoun pharmaceutical egypt largest drugmaker help expand middle east africa valeant earlier year buy salix pharmaceutical have be rumore be interested animal medicine company zoetis zts zoetis be also weekly review report result aug profit period be see flat cent share decline sale zoetis be secondary buy range rebound week line valeant lead highly rate medical ethical drug industry best possible composite rating comprise key ibd metric zoetis rating be medical product group also highly rate be lead abiom abmd cambrex cbm enjoy top notch fundamental abiom maker heart pump be approach cup type base buy point report earning aug profit be see cent share vs loss cent year earlier quarter sale be expect jump cambrex help drug company develop process manufacture drug be nearly past buy point cup handle base level investor consider take profit many stock correct point
212,ZTS,unsettled market make sense err side caution sometimes mean focuse less aggressive growth small cap name more liquid large cap name find week big cap big cap component be generally less volatile small cap name partly due heavy mutual fund sponsorship name
213,ZTS,share zoetis zts friday more erased thursday surge talk valeant be eyee animal health company zoetis share plummet stock market today activist investor bill ackman hedge fund persh square be company largest shareholder stake valeant pharmaceutical vrx reportedly make preliminary approach
214,ZTS,animal health company zoetis zts early tuesday beat analyst estimate guide consensus send share early trading tuesday
215,ZTS,zoetis say sale rise year earlier quarter vs analyst consensus adjust net income be cent share beating estimate cent company do not offer year comparison latter likely be then still part pfizer pfe spinoff start trading price share feb
216,ZTS,zoetis stock be early trading stock market today earlier session share fall time low stock first day trading
217,ZTS,zoetis guide revenue last year miss analyst ep guide be also modestly last year consensus
218,ZTS,isi group analyst mark schoenebaum partly defend company point guidance include worth foreign exchange rate drag be not mentioned zoetis earning release impact account guidance be roughly line wall street write email client
219,ZTS,acknowledge however be gross margin expansion year investor have be hope conference call discuss result zoetis cfo richard passov say be year peak synergy imply margin expansion improve later
220,ZTS,follow amy reeve twitter ibd_areeve animal health company zoetis zts early tuesday beat analyst estimate guide consensus send share early trading tuesday zoetis say sale rise year earlier quarter vs analyst consensus adjust net income be cent share beating estimate cent company do not offer year comparison latter likely be then still part pfizer pfe spinoff start trading price share feb zoetis stock be early trading stock market today earlier session share fall time low stock first day trading zoetis guide revenue last year miss analyst ep guide be also modestly last year consensus isi group analyst mark schoenebaum partly defend company point guidance include worth foreign exchange rate drag be not mentioned zoetis earning release impact account guidance be roughly line wall street write email client acknowledge however be gross margin expansion year investor have be hope conference call discuss result zoetis cfo richard passov say be year peak synergy imply margin expansion improve later follow amy reeve twitter ibd_areeve
221,ZTS,alibaba world largest online retailer have enthralled investor be largest tech initial public offer history eye pop market value make china online shopping sale eclipse amazon com amzn ebay ebay combine chinese medium report here
222,ZTS,antero resource ar oil gas firm go public last month get green light investment number analyst monday stock continue be best ipos year antero be initiate overweight rating jpmorgan price target barclay also give overweight rating
223,ZTS,swiss giant pharma novartis nvs monday announce agree sell blood transfusion diagnostic unit spain grifol grfs send stock stock market grifol say deal complement core plasma business diagnostic technology also strengthen business production plant emeryville calif novartis
224,ZTS,share big pharma merck mrk gap stock market tuesday morning company announce restructure say save merck say news release cut job global workforce top job cut have already be
225,ZTS,drugmaker pfizer pfe announce tuesday spin rest animal health unit zoetis zts june just shy month sell ipo
226,ZTS,pfizer accomplish optional share exchange pfizer shareholder swap number share equivalent zoetis share discount market price perhaps reason zoetis share drop stock market wednesday morning pfizer gap more
227,ZTS,overall share exchange be earlier expect believe positive event pfe stock write analyst mark schoenebaum isi group email client
228,ZTS,pfizer say press release income ipo share reduction exchange more make lose income spinoff make deal accretive company have also be organize remain business cluster research drive innovation business steadier value business prepare possible split however company earning call last month ceo ian read say such split wouldn occur earliest drugmaker pfizer pfe announce tuesday spin rest animal health unit zoetis zts june just shy month sell ipo pfizer accomplish optional share exchange pfizer shareholder swap number share equivalent zoetis share discount market price perhaps reason zoetis share drop stock market wednesday morning pfizer gap more overall share exchange be earlier expect believe positive event pfe stock write analyst mark schoenebaum isi group email client pfizer say press release income ipo share reduction exchange more make lose income spinoff make deal accretive company have also be organize remain business cluster research drive innovation business steadier value business prepare possible split however company earning call last month ceo ian read say such split wouldn occur earliest
229,ZTS,big pharma pfizer pfe partly own veterinary business zoetis zts be set report earning open tuesday stock struggle recent setback pfizer be still shrink mode loss patent exclusivity major drug analyst poll thomson reuter expect sale decline
230,ZTS,big pharma pfizer pfe animal health affiliate zoetis zts deliver sharply different earning report early tuesday send stock different direction zoetis bring good news adjust net income be cent share year earlier quarter top analyst estimate cent sale rise slightly consensus company
231,ZTS,market initial public offering be strong start ipos have raise fuel strong growth stock market index accord report young ipos more day go compare look ahead second
232,ZTS,share drug giant pfizer pfe animal health affiliate zoetis zts moved opposite direction tuesday company report sharply different first quarters
233,ZTS,zoetis bring good news adjust net income reach cent share year earlier top analyst estimate cent sale rise slightly view
234,ZTS,full year guidance be line consensus estimate ep sale last year company make cent share revenue
235,ZTS,ipo month
236,ZTS,zoetis partly spun pfizer ipo month perform best sale rise grow less europe do better have fear french competitor virbac report earlier april
237,ZTS,be obvious weakness europe fact region include europe report revenue growth year year be excellent opinion write analyst mark schoenebaum isi group email client
238,ZTS,conference call analyst discuss result ceo juan ramon alaix admit livestock portion zoetis business have hit head wind especially recent drought say sale pet market make difference be help partly now resolve supply issue rival
239,ZTS,say company be optimistic pet market think have have right strategy right program also interaction customer direct interaction customer
240,ZTS,zoetis share spiked much early fall back bit close
241,ZTS,pfizer meanwhile issue much gloomier report sale shrank miss estimate profit fall cent share penny consensus
242,ZTS,pfizer also shave full year revenue forecast be now vs last year also cut cent ep guidance be now vs last year
243,ZTS,revenue miss revenue guidance cut be due unfavorable foreign exchange rate
244,ZTS,be also timing issue center disease control purchase pneumococcal vaccine prevnar sale come consensus
245,ZTS,ep guidance be hit foreign exchange rate zoetis divestment latter peel cent conference call pfizer ceo ian read say executive be still make mind divest zoetis pfizer still own also address prospect rest pfizer eventually split company much abbott laboratory abbvie abbv do earlier year already company be be organized core business read say win be ready separate earliest
246,ZTS,potential blockbuster
247,ZTS,research note morningstar analyst damien conover call quarter minor disappointment say didn affect longer term positive view say sale have be shrink due patent loss quarter bring launch potential blockbuster anticoagulant eliquis jointly own bristol myer squibb bmy oral rheumatoid arthritis drug xeljanz xeljanz be reject european union authority last week conover say pfizer succeed refile
248,ZTS,other analyst have call eliquis launch weak read characterize line expectation xeljanz wasn fully launch march read say re encourage early indication indicator re see
249,ZTS,pfizer stock fall tuesday close share drug giant pfizer pfe animal health affiliate zoetis zts moved opposite direction tuesday company report sharply different first quarters zoetis bring good news adjust net income reach cent share year earlier top analyst estimate cent sale rise slightly view full year guidance be line consensus estimate ep sale last year company make cent share revenue ipo month agozoetis partly spun pfizer ipo month perform best sale rise grow less europe do better have fear french competitor virbac report earlier april be obvious weakness europe fact region include europe report revenue growth year year be excellent opinion write analyst mark schoenebaum isi group email client conference call analyst discuss result ceo juan ramon alaix admit livestock portion zoetis business have hit head wind especially recent drought say sale pet market make difference be help partly now resolve supply issue rival say company be optimistic pet market think have have right strategy right program also interaction customer direct interaction customer zoetis share spiked much early fall back bit close pfizer meanwhile issue much gloomier report sale shrank miss estimate profit fall cent share penny consensus pfizer also shave full year revenue forecast be now vs last year also cut cent ep guidance be now vs last year revenue miss revenue guidance cut be due unfavorable foreign exchange rate be also timing issue center disease control purchase pneumococcal vaccine prevnar sale come consensus ep guidance be hit foreign exchange rate zoetis divestment latter peel cent conference call pfizer ceo ian read say executive be still make mind divest zoetis pfizer still own also address prospect rest pfizer eventually split company much abbott laboratory abbvie abbv do earlier year already company be be organized core business read say win be ready separate earliest potential blockbustersin research note morningstar analyst damien conover call quarter minor disappointment say didn affect longer term positive view say sale have be shrink due patent loss quarter bring launch potential blockbuster anticoagulant eliquis jointly own bristol myer squibb bmy oral rheumatoid arthritis drug xeljanz xeljanz be reject european union authority last week conover say pfizer succeed refile other analyst have call eliquis launch weak read characterize line expectation xeljanz wasn fully launch march read say re encourage early indication indicator re see pfizer stock fall tuesday close
250,ZTS,zoetis zts animal health company be spun pfizer pfe be early friday morning ipo price company expect range
251,ZTS,zoetis raise price offer share previously state range be biggest ipo raise facebook fb rake last company sell share pfizer retain control share pfizer expect spin rest point hasn set timeline
252,ZTS,zoetis be largest player industry more annual revenue ibd profile company monday financial industry player say be perceive great interest offer zoetis have be grow even parent have be shrink due patent loss
253,ZTS,veterinary drugmaker don face same patent regime cover human drug also don have high margin blockbuster
254,ZTS,related pfizer stock hit high earning talk split zoetis zts animal health company be spun pfizer pfe be early friday morning ipo price company expect range zoetis raise price offer share previously state range be biggest ipo raise facebook fb rake last company sell share pfizer retain control share pfizer expect spin rest point hasn set timeline zoetis be largest player industry more annual revenue ibd profile company monday financial industry player say be perceive great interest offer zoetis have be grow even parent have be shrink due patent loss veterinary drugmaker don face same patent regime cover human drug also don have high margin blockbuster related pfizer stock hit high earning talk split
255,ZTS,stock add early gain rise trade midday federal reserve chairman ben bernanke tell congress tighten monetary policy be premature dow jone industrial average lead gain also jump nasdaq be ahead volume picked board rise nasdaq
256,ZTS,silkroad maker human resource software have select investment banker ipo follow footstep rival workday wday accord anonymously source report reuter reuter story say silkroad hire jpmorgan piper jaffray lead underwriter employment suggest offer be substantial size contrast
257,ZTS,venture backed startup turn ipos slower rate acquisition slowest pace datum release monday show
258,ZTS,new report national venture capital association thomson reuter say growth be expect later year note new ipos trade offer price
259,ZTS,most ipos report cite be information technology rest be biotech medical field largest be modeln modn maker revenue management software life science tech industry raise
260,ZTS,be just initial public offering venture backed startup raise less same number ipos raise fourth quarter nvca thomson reuter say monday
261,ZTS,first quarter ipos ibd have written include printer maker exone co xone internet money transfer firm xoom xoom electric utility smart grid network enabler silver spring network ssni ad management firm marin software mrin pfizer pfe animal health spinoff zoetis zts molecular technology biotech entanta pharmaceutical exone be most debut other be flat have fall zoetis be
262,ZTS,nvca thomson reuter figure be ipos total dollar term average raise ipo fall
263,ZTS,first quarter ipo acquisition activity be often subdue year end report forward plan take priority year political taxation sequestration concern weigh even more heavily exit market emerge growth company john taylor research chief nvca say monday report
264,ZTS,note public market valuation have be lately say quality company tell be start process exit later year
265,ZTS,see stronger volume likely second third quarter say quality company go public get acquire have be solid environment
266,ZTS,be venture backed company pipeline have file ipo security exchange commission nvca say job act go effect april enable confidential registration nvca say many observer say most vc backed startup take ipo path
267,ZTS,report note venture backed deal have aggregate value largest merger acquisition transaction count be illumina ilmn purchase verinata health second be medicine co mdco acquisition incline therapeutic
268,ZTS,report figure only account deal disclose value venture backed startup turn ipos slower rate acquisition slowest pace datum release monday show new report national venture capital association thomson reuter say growth be expect later year note new ipos trade offer price most ipos report cite be information technology rest be biotech medical field largest be modeln modn maker revenue management software life science tech industry raise be just initial public offering venture backed startup raise less same number ipos raise fourth quarter nvca thomson reuter say monday first quarter ipos ibd have written include printer maker exone co xone internet money transfer firm xoom xoom electric utility smart grid network enabler silver spring network ssni ad management firm marin software mrin pfizer pfe animal health spinoff zoetis zts molecular technology biotech entanta pharmaceutical exone be most debut other be flat have fall zoetis be nvca thomson reuter figure be ipos total dollar term average raise ipo fall first quarter ipo acquisition activity be often subdue year end report forward plan take priority year political taxation sequestration concern weigh even more heavily exit market emerge growth company john taylor research chief nvca say monday report note public market valuation have be lately say quality company tell be start process exit later year see stronger volume likely second third quarter say quality company go public get acquire have be solid environment be venture backed company pipeline have file ipo security exchange commission nvca say job act go effect april enable confidential registration nvca say many observer say most vc backed startup take ipo path report note venture backed deal have aggregate value largest merger acquisition transaction count be illumina ilmn purchase verinata health second be medicine co mdco acquisition incline therapeutic report figure only account deal disclose value
269,ZTS,exchange trade fund create track basket initial public offering renaissance ipo etf ipo have own ipo new york stock exchange wednesday aptly trading ticker ipo etf create renaissance capital greenwich conn pound gorilla ipo research investment management start trading
270,ZTS,oil natural gas company antero resource ar lead parade stock first day trading thursday rise more early day antero raise ipo second biggest ipo year base company produce gas rich shale oilfield west virginia ohio pennsylvania begin trading
271,ZTS,equity market boom first quarter ipo investor play safe modest number deal heavy dividend pay stock analyst say thing get more interesting year go total ipos come quarter first quarter last year accord
272,ZTS,animal health company zoetis zts finally left nest week become far largest freestand company industry market parent pfizer pfe sell chunk ownership zoetis ipo month raise more big pharma be lose biggest revenue stream due patent expiration
273,ZTS,buzz be anyone try raise ipo market zoetis be not typical ipo company comprise animal health business giant pharma pfizer pfe have be selling core division make lose blockbuster drug more annual
274,ZTS,abaxis inc abax free report be close heel takeover bid zoetis inc zts free report be announce last end company recently state wait period hart scott rodino antitrust improvement act hsr act have expire transaction be still subject other customary close condition include approval abaxis shareholder accordingly jul company stockholder vote transaction soon acquisition get close meanwhile let glance deal detail once again animal health company zoetis have make cash offer share total value abaxis shareholder be premium close abaxis share price denote figure just news release expect synergy adoption abaxis point care diagnostic instrument zoetis expect consolidated company veterinary diagnostic category grow faster animal health industry management integration fetch significant synergy benefit company abaxis announce have recently invest expand operation europe latin america asia pacific region revenue expect be draw internationally fiscal meanwhile zoetis already have substantial global presence direct veterinary customer relationship deliver greater value more customer worldwide undoubtedly buyout discussion then accelerate growth combine entity overseas business market market report veterinary diagnostic market be anticipate witness cagr reach value share price performancein past month share abaxis have rally outperform industry growth zack rank key picksabaxis currently carry zack rank hold better rank stock broader medical space be genomic health ghdx free report align technology inc algn free report genomic health have expect earning growth rate quarter be report stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
275,ZTS,zoetis inc zts free report announce wait period hart scott rodino antitrust improvement act hsr act have expire relation propose acquisition abaxis inc abax free report company enter agreement zoetis agree acquire abaxis cash offer share approximately aggregate deal be subject customary close condition include regulatory approval well consent abaxis shareholder vote transaction special meeting schedule be hold july zoetis expect complete acquisition year end intend fund purchase combination exist cash new debt notably california base abaxis be engage manufacturing develop portable blood analysis system used broad range medical specialty human veterinary patient care provide clinician rapid blood constituent measurement buyout be expect boost zoetis presence veterinary diagnostic portion animal health market zoetis get access abaxis vetscan portfolio bench top handheld diagnostic instrument consumable transaction also enable company support veterinarian provide comprehensive solution predict prevent detect treat disease animal diagnostic category be fast grow space animal health industry have witness cagr approximately last year zoetis expect veterinary diagnostic category continue grow more rapidly animal health industry thus register mid high single digit improvement company project transaction be accretive bottom line share zoetis have rally year date outperform industry increase zoetis currently carry zack rank hold better rank stock pharma sector include genomic health inc ghdx free report taro pharmaceutical industry ltd taro free report sporting zack rank strong buy see complete list today zack rank stock here genomic health earning estimate have be revise upward past day stock have soar so far year taro pharmaceutical earning estimate have moved north past day stock have gain so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
276,ZTS,investor interested stock medical drug sector have probably already hear catalent ctlt free report zoetis zts free report stock present investor better value opportunity right now let take closer look have find best way great value opportunity be pair strong zack rank great grade value category style score system proven zack rank emphasize company positive estimate revision trend style score highlight stock specific trait right now catalent be sporting zack rank buy zoetis have zack rank hold zack rank favor stock have recently see positive revision earning estimate so investor rest assured ctlt have improve earning outlook be just factor value investor be interested value investor also try analyze wide range traditional figure metric help determine company be undervalue current share price level value category highlight undervalue company look variety key metric include popular ratio well ratio earning yield cash flow share variety other fundamental have be used value investor year ctlt currently have forward ratio zts have forward also note ctlt have peg ratio metric be used similarly famous ratio peg ratio also take account stock expect earning growth rate zts currently have peg ratio notable valuation metric ctlt be ratio ratio be used compare stock market value book value be defined total asset total liability comparison zts have be just few metric contribute ctlt value grade zts value grade ctlt be currently sporting improve earning outlook make stick zack rank model base valuation metric feel ctlt be likely superior value option right now
277,ZTS,month have go last earning report zoetis inc zts free report share have add time frame recent positive trend continue lead next earning release be zts due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst zoetis beat earning sale retain viewzoetis post first quarter adjust earning share exclude time item increase year year beat zack consensus estimate total revenue rise year year operationally exclude impact currency quarter beat zack consensus estimate quarterly report business result geographical operate segment unite state international company have diverse portfolio product livestock companion animal revenue unite state segment increase year year sale companion animal product region be primarily due higher sale dermatology portfolio new product launch be partially offset lower sale line product livestock revenue increase mainly due increase sale cattle poultry product partially offset decline dairy product revenue international segment grow year year operationally report basis livestock sale be report basis operationally quarter mainly drive strong growth cattle poultry product moreover sale companion animal product grow report basis operational basis reflect higher sale dermatology portfolio newly launch product especially simparica outlook reiterate outlook company continue expect adjust earning range share revenue be expect range zack consensus estimate earning revenue be peg share respectively other company continue expand availability oral flea tick medication simparica new market additional approval thailand serbia zoetis canine dermatology product cytopoint receive approval mexico switzerland unite state company enhance swine vaccine franchise approval fostera gold pcv mh protection pcv mycoplasma hyopneumoniae moreover inforce respiratory disease vaccine receive approval korea egypt treatment mastitis dairy cow spectramast dc be approve china have estimate be move then past month investor have witness downward trend fresh estimate have be revision lower current quarter zoetis inc price consensus zoetis inc price consensus zoetis inc quotevgm scoresat time zts have strong growth score be lag bit momentum front charting somewhat similar path stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be primarily suitable growth investor also be suitable look momentum lesser degree value outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably zts have zack rank hold expect line return stock next few month
278,ZTS,week astrazeneca azn free report novartis nvs free report eli lilly lly free report announce regulatory pipeline update line extension market drug astrazeneca asthma drug fasenra fail meet primary endpoint late stage study evaluate expand indication chronic obstructive pulmonary disease copd lilly migraine candidate galcanezumab meet same late stage study evaluate indication prevention episodic cluster headache novartis multiple sclerosis ms drug gilenya gain fda approval use adolescent cgrp antibody aimovig also gain fda approval prevention migraine zoetis zts free report lilly announce acquisition deal recap week most important storieslilly buy small cancer biotech lilly have agree buy early phase oncology asset ak aurka pharma expand oncology pipeline lilly make upfront payment acquire share aurka pharma be lilly second cancer acquisition less week last week lilly have announce cash deal tobuy immuno oncology biotech armo bioscience read more eli lilly buy aurka pharma expand cancer pipeline development migraine candidate galcanezumab meet primary endpoint late stage study evaluate indication prevention episodic cluster headache galcanezumab be already review unite state migraine prevention decision expect third quarter year however separate phase iii study evaluate galcanezumab patient chronic cluster headache do not meet primary endpoint read more eli lilly cluster headache candidate succeed phase iii zoetis buy abaxis zoetis announce definitive agreement buy california base abaxis be lead global provider veterinary point care diagnostic instrument approximately share cash deal be aim enhance zoetis presence animal health diagnostic market diagnostic category be fast grow portion animal health industry have grow compound annual growth rate approximately last year read more zoetis inks deal acquire abaxis novartis aimovig get fda nod novartis partner amgen amgn free report gain fda approval cgrp antibody aimovig prevention migraine fda approval aimovig be now first only fda approve treatment migraine work block calcitonin gene related peptide receptor cgrp play critical role migraine attack meanwhile lilly teva pharmaceutical industry ltd teva free report be also await fda approval cgrp migraine candidate galcanezumab fremanezumab year novartis ms drug gilenya gain fda approval treatment child adolescent age relapse form multiple sclerosis approval expand patient population boost sale gilenya drug record sale first quarter represent year year growth rate constant currency basis read more novartis multiple sclerosis drug get fda nod adolescent astrazeneca fasenra fail meet endpoint phase iii copd study astrazeneca respiratory biologic medicine fasenra benralizumab fail meet primary endpoint late stage study evaluate new indication severe copd fasenra be already approve unite state eu japan add maintenance treatment patient severe eosinophilic asthma top line result pivotal phase iii galathea study show treatment fasenra do not result statistically significant reduction exacerbation compare placebo patient moderate very severe copd read more astrazeneca asthma drug fasenra fail copd study astrazeneca announce weak first quarter result miss zack consensus estimate earning sale due lower sale cholesterol drug crestor maintain previously issue outlook pfizer biosimilar retacrit get fda nod pfizer pfe free report retacrit be biosimilar version anemia drug amgen epogen jnj free report procrit gain fda approval indication reference product include treatment anemia due chronic kidney disease ckd pfizer already market biosimilar europe last year fda advisory committee have recommend approval retacrit read more pfizer get fda nod amgen anemia drug biosimilar fda name drugmaker block approval generic fda issue list company week say be used certain gaming tactic delay generic competition market drug fda say company be prevent generic player obtain necessary sample brand product be require secure approval generic drug inability secure such sample slow approval process list include big name shire novartis mylan astrazeneca teva biomarin gilead bayer other fda decision publish such list be part broader effort congress encourage approval low cost generic drug nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week decline bristol myer rise most past month glaxo gsk free report have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup lly buy cancer biotech azn roche announce update next pharma world watch fda decision many pipeline drug line extension market product month more stock news be bigger iphoneit become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
279,ZTS,share abaxis inc abax free report sky-rocket soon acquisition news grab headline stock jump more yesterday follow animal health company zoetis inc zts free report announcement buy abaxis approximate deal value deal glancezoetis have make cash offer share abaxis shareholder be premium close abaxis share price denote price just news release banking exciting deal share abaxis rise wednesday reflect time high company later close price higher offer value abaxis inc price abaxis inc price abaxis inc quote transaction be expect complete end subject customary close condition regulatory approval abaxis stakeholder consent expect synergy adoption abaxis point care diagnostic instrument zoetis expect consolidated company veterinary diagnostic category grow faster animal health industry management integration bring significant synergy benefit company abaxis state have recently invest expand operation europe latin america asia pacific region revenue expect be draw internationally fiscal meanwhile zoetis already have substantial global presence direct veterinary customer relationship deliver greater value more customer worldwide undoubtedly buyout accelerate growth combine entity overseas business market market report veterinary diagnostic market be anticipate witness cagr reach value financial impact acquisition adjust basis zoetis do not expect immediate material impact merged company earning transaction be however likely be accretive bottom line share price performancein past month abaxis share have rally outperform industry gain zack rank key picksabaxis currently carry zack rank hold better rank stock broader medical space be genomic health inc ghdx free report varian medical system inc var free report genomic health have expect growth rate stock sport zack rank strong buy see complete list today zack rank stock here varian medical have project long term growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
280,ZTS,first century fox inc foxa free report share gain company settle lawsuit former employee fox news channel have sue company allege racial gender holding inc iqv free report decrease fda raise serious concern company datum related controlled substance prescription fentanylabaxis inc abax free report share jump animal health company zoetis inc zts free report agree buy cashshare teva pharmaceutical industry ltd teva free report rise warren buffet berkshire hathaway inc brk free report more double investment company
281,ZTS,zoetis inc zts free report announce definitive deal acquire caifornia base abaxis inc abax free report lead global provider veterinary point care diagnostic instrument share cash total price offer zoetis represent premium abaxis close share abaxis go follow news acquisition share zoetis have increase year date industry decline deal be expect boost zoetis presence veterinary diagnostic portion animal health market sector have witness annual compound growth rate past year acquisition zoetis get access abaxis vetscan portfolio bench top handheld diagnostic instrument consumable zoetis plan provide broader range veterinary diagnostic product leverage global scale direct customer relationship zoetis expect veterinary diagnostic category continue grow faster animal health industry growth mid high single digit abaxis derive annual revenue fiscal diagnostic product service veterinary market company revenue fiscal end mar be derive diagnostic product service veterinary market deal be subject customary close condition include regulatory approval approval abaxis shareholder zoetis expect complete acquisition end intend fund purchase combination exist cash new debt company expect transaction be accretive company earning zack rank stock considerzoetis carry zack rank hold few better rank stock same space worth consider be ligand pharmaceutical lgnd free report enanta pharmaceutical inc enta free report ligand sport zack rank strong buy enanta carry zack rank buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date enanta searning share estimate have moved cent past day company deliver positive earning surprise trail quarters average beat stock have rally so far year zoetis inc price zoetis inc price zoetis inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
282,ZTS,zoetis inc zts free report post first quarter adjust earning cent share exclude time item increase year year beat zack consensus estimate cent total revenue rise year year operationally exclude impact currency quarter beat zack consensus estimate look zoetis share price movement show stock have outperformed industry year date basis stock have gain industry decline quarterly report business result geographical operate segment unite state international company have diverse portfolio product livestock companion animal revenue unite state segment increase year year sale companion animal product region be primarily due higher sale dermatology portfolio new product launch be partially offset lower sale line product livestock revenue increase mainly due increase sale cattle poultry product partially offset decline dairy product revenue international segment grow year year operationally report basis livestock sale be report basis operationally quarter mainly drive strong growth cattle poultry product moreover sale companion animal product grow report basis operational basis reflect higher sale dermatology portfolio newly launch product especially simparica outlook reiterate outlook company continue expect adjust earning range share revenue be expect range zack consensus estimate earning revenue be peg share respectively other company continue expand availability oral flea tick medication simparica new market additional approval thailand serbia zoetis canine dermatology product cytopoint receive approval mexico switzerland unite state company enhance swine vaccine franchise approval fostera gold pcv mh protection pcv mycoplasma hyopneumoniae moreover inforce respiratory disease vaccine receive approval korea egypt treatment mastitis dairy cow spectramast dc be approve china takezoetis first quarter result exceed earning sale expectation zoetis become first animal health company deliver more revenue company continue achieve operational revenue growth drive diversity product portfolio balanced performance unite state major international market company expect improve work capital fund investment support ability create long term value shareholder zoetis inc price consensus ep surprise zoetis inc price consensus ep surprise zoetis inc quotezack rank stock considerzoetis currently carry zack rank hold better rank stock same space be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report catabasis pharmaceutical catb free report whlle ligand protagonist therapeutic sport zack rank strong buy catabasis carry zack rank buy see complete list today zack rank stock here ligand earning share estimate moved remain stable last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist therapeutic loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat catabasis loss estimate narrow cent cent last day company come positive earning surprise precede quarters average beat stock have rally year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
283,ZTS,florham park nj base zoetis inc zts free report be lead global animal health company focuse discovery development manufacture animal health medicine vaccine focus livestock companion animal company come existence follow pfizer decision spin animal health business zoetis diversify portfolio product livestock companion animal continue drive top line growth company company top line continue benefit addition product acquire abbott laboratory february pharmaq november nexvet july well performance apoquel other key brand scenario investor focus remain top bottom line number zoetis track record have be impressive company beating earning estimate consistently fact zoetis earning surpass expectation last quarters average positive surprise currently zoetis have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat zoetis report earning share cent beating zack consensus estimate cent first quarter revenue beat zoetis post revenue slightly surpass zack consensus estimate key stat first quarter zoetis receive approval swine vaccine fostera unite state company continue expand availability companion animal product cytopoint receive approval mexico switzerland simparica be approve thailand serbia several major cattle product include inforce spectramast dc also receive approval new geography outlook reiterate zoetis maintain outlook company expect adjust earning range share revenue zack consensus estimate earning be share revenue share price impact share company be pre market trading check back later full zts earning report later zoetis inc price ep surprise zoetis inc price ep surprise zoetis inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
284,ZTS,zoetis inc zts free report be schedule report first quarter result open bell zoetis performance have be encourage company surpass expectation previous quarters average positive earning surprise last quarters be zoetis share price movement show stock have outperformed industry year date basis stock have moved industry decline period let see thing be shape announcement factor considerzoetis derive majority revenue diversify product portfolio medicine vaccine used treat protect livestock companion animal company continue strengthen diverse product portfolio lifecycle innovation strong customer relationship access new market technology company report impressive result mainly drive strong demand companion animal business zoetis dermatology drug apoquel cytopoint simparica have perform well due increase penetration continue uptake expect trend positively impact first quarter result moreover company be work expand reach simparica receive approval several country new indication fourth quarter further boost sale december company announce launch vanguard civ latest vaccine company canine influenza virus civ portfolio fourth quarter livestock sale be drive sale cattle poultry product however favorable weather drive incidence disease risk higher cattle expect company throw more light acquisition strategy impact pipeline follow acquisition nexvet biopharma innovator monoclonal antibody therapy companion animal july model proven model show do not conclusively show earning beat zoetis be report quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate loss cent zack consensus estimate loss cent be uncover best stock buy sell re report earning esp filter zack rank zoetis currently have zack rank increase predictive power esp however need have positive esp be confident earning beat note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision zoetis inc price ep surprise zoetis inc price ep surprise zoetis inc quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat upcoming release emergent biosolution inc ebs free report have earning esp zack rank company be schedule release result see complete list today zack rank stock here vanda pharmaceutical inc vnda free report have earning esp zack rank company be schedule release first quarter result adverum biotechnology inc advm free report have earning esp currently carry zack rank company be expect release first quarter result hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
285,ZTS,merck co inc mrk free report announce committee medicinal product veterinary use cvmp have recommend marketing authorization europe bravecto spot combination topical solution fluralaner moxidectin cat bravecto be part company animal health unit company share be so far year industry gain period veterinary medicinal product approval be used treatment internal external parasite infestation tick flea heartworm roundworm hookworm cat drug start kill activity tick flea immediately continue week prevent heartworm disease week bravecto be first approve chewable tablet formulation dog spot version be launch topical solution dog cat unite state bravecto be major growth driver animal health unit due rise demand formulation bravecto be ultimately approve eu sale product increase further however product company animal health unit face competition product other company zoetis inc zts free report eli lilly company lly free report elanco generic product merck co inc price merck co inc price merck co inc quotezack rank stock considermerck currently carry zack rank hold pfizer inc pfe free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here pfizer earning estimate increase last day company deliver positive earning surprise trail quarters average beat hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
286,ZTS,have be month last earning report zoetis zts free report share have add time frame recent positive trend continue lead next earning release be zts due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver zoetis beat earning sale give viewzoetis post fourth quarter adjust earning share exclude time item provisional net tax charge related recently enact tax legislation unite state increase year year beat zack consensus estimate total revenue rise year year operationally exclude impact currency quarter beat zack consensus estimate quarterly report business geographical operate segment unite state international company have diverse portfolio product livestock companion animal revenue unite state segment be year year sale companion animal product region be primarily due higher sale dermatology portfolio new product launch especially simparica livestock revenue increase mainly due increase sale cattle poultry product partially offset decline swine product revenue international segment grow year year operationally report basis livestock sale be report basis operationally quarter mainly drive balanced growth portfolio moreover sale companion animal product grow report basis operational basis reflect higher sale dermatology portfolio simparica resultsadjust earning come share year year exceed zack consensus estimate company post revenue increase result surpass zack consensus estimate outlookzoetis provide outlook company expect adjust earning range share revenue be expect range zack consensus estimate earning revenue be peg share respectively other company continue expand availability oral flea tickmedication simparica new market additional approval chile panama philippine switzerland product also receive approval european union treatment additional type skin mite unite state company enhance medicated feed additive portfolio expand claim lincomix lincomycin hydrochloride popular feed medication have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter zoetis inc price consensus zoetis inc price consensus zoetis inc quotevgm scoresat time zts have great growth score be lag lot momentum front follow exact same course stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable growth investor look value momentum outlookestimate have be trend upward stock magnitude revision look promising interestingly zts have zack rank hold expect line return stock next few month
287,ZTS,pharma biotech stock kick strong note carry momentum gain last year sector have be struggle lately probably broader market pressure be expect rebound year progress innovation merger acquisition strong result product approval positive datum flow act catalyst pharma biotech stock accelerate last year be not particularly great far deal be concern industry bellwether johnson johnson acquire actelion approximately gilead acquire kite however year expectation increase activity be high new tax law cut corporate tax rate encourage company bring back cash hold overseas time tax rate be expect spur merger activity sanofi sny free report celgene celg have already announce deal so far year sanofi announce deal buy belgian biotech company ablynx hemophilia focuse biotech bioverativ bivv celgene announce deal buy juno therapeutic inc juno focus development car therapy impact biomedicine add late stage jak kinase inhibitor celgene pipeline merck mrk free report recently announce have propose buy australian oncolytic immunotherapy maker viralytic ltd strengthen presence fast grow immuno oncology market company be look replace sale blockbuster product be face loss patent exclusivity other be look build pipeline acquisition well licensing agreement company innovative technology pipeline be highly seek niche disease area nonalcoholic steatohepatitis nash immuno oncology multiple sclerosis be demand treatment orphan disease be also much seek quite few deal be sign area gilead gild free report kite celgene juno acquisition approval car therapy unite state last year novartis nvs free report kymriah gilead yescarta interest immuno oncology have picked significantly innovative pipelinespharma biotech company continue work bring innovative treatment market be significant catalyst come quarters form important new product approval well major datum read out especially key therapeutic area immuno oncology alzheimer central nervous system disorder immunology inflammation cancer remain key therapeutic several new treatment have emerge field cancer interest area remain high disease be lead cause morbidity mortality world even lot progress have be make area company be aim bring newer better treatment focus area have increase recent fda approval car therapy kymriah yescarta approval kymriah yescarta mark begin new era treatment cancer path breaking immunocellular therapy be time treatment used patient own cell fight cancer acquisition kite gilead potential acquisition juno celgene have lead renew interest area major player field include bristol myer novartis astrazeneca merck roche immuno oncology deal be be inked company pfizer pfe free report celgene merck kgaa bristol myer bmy astrazeneca azn abbvie abbv incyte incy free report interest parp inhibitor have also increase considerably well be next major class therapeutic oncology accord imsquintile new cancer drug be approve indication worldwide cost cancer therapeutic supportive care drug shot unite state accounting cost more molecule be late stage development majority be target therapy new product sale ramp upsale product have gain approval last year well line usage extension boost growth recent entrant novartis psoriasis treatment cosentyx merck pd inhibitor keytruda pfizer cancer treatment ibrance have already achieve blockbuster status be key contributor top line meanwhile cancer treatment lynparza kyproli keytruda opdivo imbruvica also bring more sale thank label expansion higher number drug approve fda grant approval novel drug more double last year total tally key approval year include novartis kymriah first gene therapy unite state lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease abbvie mavyret hcv gilead yescarta other quite few drug have blockbuster potential key drug currently fda review decision expect couple month include teva fremanezumab migraine amgen aimovig prevention migraine apalutamide pre metastatic prostate cancer abbvie elagolix endometriosis associate pain meanwhile agency be work streamline development process drug rare disease well target cancer therapy earlier month fda propose new guideline be aim lower clinical study goal treatment be develop neurological disorder such muscular dystrophy amyotrophic lateral sclerosis al alzheimer disease ad migraine epilepsy aren adequately address available therapy fda be also work clear backlog orphan drug application accord imsquintile report late phase pipeline industry indicate be new brand launch year tech tie up pick internet medical thing iomt well be future healthcare pharma company look innovate keep technology help patient physician better monitor track disease iomt involve bring together technology medical device application chronic disease require frequent monitoring be track effectively so patient receive timely proper treatment wearable device apple watch fitbit samsung health help user achieve fitness health target pharma tech company be now take thing step further collaborate make device track chronic lifestyle associate disease diabetes be become rampant fact scope innovation area contact lense detect glucose level device monitor caloric intake bioelectronic medicine treat wide range chronic disease robotic assist surgery be seemingly endless stock sector face volatility due drug pricing issue pipeline success innovative important therapeutic area cost cut share buyback new product increase pipeline visibility appropriate utilization cash help maintain investor confidence sector company pfizer abbvie nordisk nvo free report regeneron pharmaceutical inc regn free report zoetis inc zts free report bioverativ amphastar pharmaceutical inc amph horizon pharma public ltd co hznp free report summit therapeutic plc smmt free report gemphire therapeutic inc gemp free report etc be buy rank stock regeneron bioverativ be zack rank strong buy stock other carry zack rank buy see complete list today zack rank stock here conclusionall say do pharma sector fundamental remain strong robust pipeline innovative treatment impressive result grow demand drug especially rare disease age population increase health care spending support growth know more sector check latest pharma industry outlook
288,ZTS,endo international plc endp free report be global specialty healthcare company develop manufacture market distribute brand pharmaceutical generic product well medical device headquarter dublin endo offer brand prescription product include lidoderm opana percocet voltaren gel frova supprelin la vanta valstar fortesta gel pain urology endocrinology oncology zack rank strong sell stock report fourth quarter result beat estimate company have be steady decline few year now be chance rebound drug maker earning deep week endo report result fiscal fourth quarter earning continue operation be cent share beating zack consensus decline significantly report year quarter revenue come also top consensus estimate fall year year thank loss marketing exclusivity first half first file product generic version zetia generic version seroquel xr be launch look endo main segment brand pharmaceutical sale be generic pharmaceutical record sale quarter international pharmaceutical division bring sale year quarter due recent divestiture outlook aheadmanagement expect revenue earning range share metric well zack consensus estimate share respectively result analyst have be cut estimate current quarter analyst cut outlook last day earning be expect decline time period analyst have revise estimate downward current fiscal year earning estimate project fall time frame look next fiscal year analyst have slash outlook last month earning grow current consensus have dip share next endo share endo be so far year have sunk well past year comparison broader industry medical drug have manage gain respectively endo international plc price consensus endo international plc price consensus endo international plc company be currently trading forward last year be rocky endo company quickly become big litigation target state be currently be sue indiana illinois kentucky florida missouri oklahoma mississippi fraudulent marketing regard opioid drug opana lawsuit still open clear picture investor be outcome endo face damage consequence additionally brand generic business have face intense pressure thank new competitor change market condition investor want drug maker stock more term potential consider zoetis inc zts free report company develop manufacture veterinary vaccine medicine buy zack rank right now anticipate earning growth current year breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
289,ZTS,zoetis inc zts free report post fourth quarter adjust earning cent share exclude time item provisional net tax charge related recently enact tax legislation unite state increase year year beat zack consensus estimate cent total revenue rise year year operationally exclude impact currency quarter beat zack consensus estimate look zoetis share price movement show stock have outperformed industry year date basis stock have moved compare industry gain quarterly report business geographical operate segment unite state international company have diverse portfolio product livestock companion animal revenue unite state segment be year year sale companion animal product region be primarily due higher sale dermatology portfolio new product launch especially simparica livestock revenue increase mainly due increase sale cattle poultry product partially offset decline swine product revenue international segment grow year year operationally report basis livestock sale be report basis operationally quarter mainly drive balanced growth portfolio moreover sale companion animal product grow report basis operational basis reflect higher sale dermatology portfolio simparica resultsadjust earning come share year year exceed zack consensus estimate company post revenue increase result surpass zack consensus estimate outlook zoetis provide outlook company expect adjust earning range share revenue be expect range zack consensus estimate earning revenue be peg share respectively other company continue expand availability oral flea tickmedication simparica new market additional approval chile panama philippine switzerland product also receive approval european union treatment additional type skin mite unite state company enhance medicated feed additive portfolio expand claim lincomix lincomycin hydrochloride popular feed medication takezoetis fourth quarter result exceed earning sale expectation zoetis post strong performance generate revenue base strength business model growth opportunity be uniquely available animal health company achieve operational revenue growth year base diversity product portfolio balanced performance unite state major international market company expect improve work capital fund investment support ability create long term value shareholder zoetis inc price consensus ep surprise zoetis inc price consensus ep surprise zoetis inc quote zack rank other key pickszoetis carry zack rank buy other top rank stock health care space be xoma corp xoma free report exelixis exel free report enanta pharma enta free report carry zack rank see complete list today zack rank strong buy stock here xoma loss share estimate have narrow cent cent last day company pull positive earning surprise last quarters average beat share price company have sky-rocket year exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat share price company have surge year enanta pharma deliver positive surprise last quarters average beat share price company have soar year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
290,ZTS,florham park nj base zoetis inc zts free report be lead global animal health company focuse discovery development manufacture animal health medicine vaccine focus livestock companion animal company come existence follow pfizer decision spin animal health business zoetis diversify portfolio product livestock companion animal continue drive top line growth company company top line benefit addition product acquire abbott laboratory february pharma november nexvet july well performance apoquel other key brand scenario investor focus remain top bottom line number zoetis track record have be impressive company beating earning estimate consistently fact zoetis earning surpass expectation last quarters average positive surprise currently zoetis have zack rank buy definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning line zoetis report earning share cent beating zack consensus estimate cent fourth quarter revenue beat zoetis post revenue surpass zack consensus estimate key stat fourth quarter zoetis continue expand availability oral flea tick medication simparica new market additional approval chile panama philippine switzerland simparica also receive approval european union treatment additional type skin mite unite state company enhance medicated feed additive portfolio expand claim lincomix lincomycin hydrochloride popular feed medication outlook zoetis provide outlook company expect adjust earning range share revenue zack consensus estimate earning be share revenue share price impact share company be pre market trading check back later full zts earning report later zoetis inc price ep surprise zoetis inc price ep surprise zoetis inc quotezack top investment idea long term see best recommendation help find today most promising long term stock start now look portfolio feature stock income stock value investment more pick have double triple digit profit potential be rarely available public see now click here
291,ZTS,zoetis inc zts free report be schedule report fourth quarter result feb market open zoetis performance last quarters have be mixed company surpass expectation thrice meeting same once average positive earning surprise last quarters be let see thing be shape announcement zoetis share price movement year date show stock have outperformed industry stock have moved industry decline period factor considerzoetis derive majority revenue diversify product portfolio medicine vaccine used treat protect livestock companion animal company continue strengthen diverse product portfolio lifecycle innovation strong customer relationship access new market technology company companion animal business have be perform well apoquel other product launch continue drive growth company expect see stronger growth companion animal portfolio drive dermatology portfolio apoquel cytopoint further penetration simparica ongoing uptake new vaccine december company announce launch vanguard civ latest vaccine company canine influenza virus civ portfolio concurrent third quarter earning call zoetis raise outlook company expect earning range share revenue improve outlook also hint possibility better result fourth quarter zoetis complete acquisition nexvet biopharma innovator monoclonal antibody therapy companion animal july acquisition be expect strengthen zoetis pipeline solution chronic pain management dog cat represent area high need companion animal health expect management throw more light acquisition strategy zoetis be work return value shareholder form share buyback dividend company also hike dividend december be payable march model proven model show do not conclusively show earning beat zoetis quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank zoetis currently have zack rank increase predictive power esp however need have positive esp be confident earning beat note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision zoetis inc price ep surprise zoetis inc price ep surprise zoetis inc quote stock warrant lookhere be health care stock also want consider model show have right combination element post earning beat quarter alk free report be schedule release fourth quarter result feb company have earning esp zack rank see complete list today zack rank stock here anthera pharmaceutical anth free report be expect release fourth quarter result feb company have earning esp zack rank exelixis exel free report be expect release fourth quarter result feb have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
292,ZTS,teva pharmaceutical industry ltd teva free report announce have complete divestment global woman health business privately hold private equity firm cvc capital partner deal be close cash divest portfolio include product contraception fertility menopause osteoporosis category drug portfolio include ovaleap zoely seasonique colpotrophine actonel be sell outside unite state product now be sell theramex woman health unit previously hold teva sale be part teva plan divestment specialty product woman health remind investor teva have sign definitive agreement sale cvc capital partner september moreover company also sign definitive agreement foundation consumer healthcare sale plan step brand emergency contraception cvc capital partner have appoint anish mehta former head international business development allergan agn free report theramex chief executive officer separate sec filing teva report have enter settlement agreement allergan jointly dismiss work capital dispute arbitration allergan pay teva part settlement teva share rise feb follow news however share company have decline past year underperform industry decline teva decline be attribute industry pressure generic competition blockbuster drug copaxone massive debt load teva also suffer setback october mylan myl free report launch generic version mg formulation copaxone much earlier expect order combat challenge teva have divest core asset cut significant debt load aim cut global workforce more next year teva pharmaceutical industry limit price teva pharmaceutical industry limit price teva pharmaceutical industry limit quotezack rank stock considerteva carry zack rank sell zoetis inc zts free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here zoetis earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
293,ZTS,interesting day market today nasdaq lead way higher follow yesterday netflix report bell online stream medium company see better expect user growth help fuel rally take share nearly day last night news hit trader immediately start bidding nasdaq future carry morning check dave daily dive video break market action today day dave bartosiak zack com twitter bartosiastic dive chart point key price action level watch doesn stop highlight today video see free click be uncover zack rank strong buy zack rank buy stock be breaking new week high today stock have ton momentum be charge higher list stock cover today include kohl kss free report kohl corporation operate department store unite state offer private label exclusive national brand apparel footwear accessory beauty home product child man woman customer company also sell product online kohls com january operated department store fila outlet aisle clearance center kohl corporation be founder be headquarter menomonee fall wisconsin mastec mtz free report mastec inc infrastructure construction company provide engineering build installation maintenance upgrade service communication energy utility infrastructure primarily unite state canada operate segment communication oil gas electrical transmission power generation industrial other target tgt free report target corporation operate general merchandise retailer offer household essential include pharmacy beauty personal care baby care clean paper product dry grocery dairy frozen food beverage candy snack deli bakery meat produce pet supply apparel woman man boy girl toddler infant newborn well intimate apparel jewelry accessory shoe union pacific unp free report union pacific corporation subsidiary union pacific railroad company operate railroad unite state offer transportation service agricultural product include grain commodity produce grain food beverage product automotive product such finished vehicle automotive part chemical comprise industrial chemical plastic fertilizer petroleum liquid petroleum gase crude oil soda ash zoetis zts free report zoetis inc engage discovery development manufacture animal health medicine vaccine livestock companion animal unite state internationally offer infective prevent slow growth bacterium fungi protozoon vaccine be biological preparation prevent disease respiratory reproductive tract induce specific immune response parasiticide prevent eliminate external internal parasite such flea tick worm now see private trade today zack rank new addition be be share public other trade be hide everyone select member peek curtain view start today next month follow zack private buy sell real time value momentum stock etf option move insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack trade
294,ZTS,re look profitable portfolio stock offer best value growth investing try growth reasonable price garp strategy help investor gain exposure stock be undervalue have impressive growth prospect blend strategy portfolio used garp investing be expect include stock offer best value growth investing garp metric mix growth value metricsthe garp approach help stock be price market reasonable target determine fundamental analysis stock also have solid prospect term cash flow revenue earning share ep so growth metricsstrong earning growth history impressive earning prospect be main aspect garp investor borrow growth investing strategy however instead super normal growth rate pursue stock more stable reasonable growth rate be also tactic garp investor hence growth rate be consider ideal garp strategy growth metric be consider growth garp investor be return equity roe garp investor look strong higher roe compare industry average identify superior stock moreover stock positive cash flow find precedence garp plan value metricsgarp investing give priority popular value metric price earning ratio investing style pick stock higher ratio compare value investor avoid company extremely high ratio moreover price book value ratio be value metric be consider used garp principle have run screen identify stock offer solid return term screening parametersalong criterium discuss section have consider favorable zack rank strong buy buy last year ep project year ep growth rate strong ep growth history prospect ensure improve business roe past month greater industry average higher roe compare industry average indicate superior stock ratio less industry average ratio less industry indicate stock be undervalue few criterium have narrow universe stock only here be stock make screen tempur sealy international inc tpx free report be involved development manufacturing marketing bedding product north america internationally company have average quarter positive earning surprise sport zack rank see complete list today zack rank stock here msci inc msci free report be independent provider research drive insight tool institutional investor company have average quarter positive earning surprise carry zack rank zoetis inc zts free report discover develop manufacture market veterinary vaccine medicine complement diagnostic product genetic test support range service company have average quarter positive earning surprise hold zack rank carter inc cri free report be lead provider apparel related product exclusively baby young child company have average quarter positive earning surprise carry zack rank toro company ttc free report be lead worldwide provider innovative solution outdoor environment include turf snow ground engage equipment irrigation outdoor light solution company have average quarter positive earning surprise carry zack rank darden restaurant inc dri free report own operate more restaurant unite state canada generate annual sale company have average quarter positive earning surprise carry zack rank illinois tool work inc itw free report manufacture sell industrial product equipment worldwide company have average quarter positive earning surprise carry zack rank get rest stock list start putt other idea test be do research wizard stock pick back testing software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
295,ZTS,investing sound large cap pharma stock seem judicious be fundamentally lucrative ensure steady stream cash inflow investor drug sector have good run bounce back drug pricing issue dampen performance importantly sector see considerable increase new drug approval last year fda approve novel drug last year more double tally large cap pharma industry witness impressive rally decline run be propel encourage quarterly result increase demand new product sale successful innovation product line expansion strong clinical study result continue strong performance legacy product also boost sector factor be expect play instrumental role well take large cap drug sector new high industry be already so far year notably large cap pharma industry carry zack industry rank place top zack industry back testing show top zack rank industry outperform bottom half factor more pass tax overhaul bill congress be cherry top slash corporate tax rate be likely further boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location leave company extra cash hand lead strategic deal merger acquisition year be relatively fewer most drug company large market cap have see share price rise so far here present company johnson johnson jnj free report abbvie inc abbv free report zoetis inc zts free report nordisk nvo free report outperformed industry last year have potential repeat same performance johnson company stock be compare favorably gain record industry company have zack rank hold see complete list today zack rank strong buy stock here company share be boost approval drug tremfya plaque psoriasis juluca hiv several line extension major drug include xarelto simponi aria stelara imbruvicain trend be expect continue have several regulatory application label expansion key drug review potential approval line extension certainly boost company growth prospect meanwhile be several pivotal datum readout regulatory milestone line moreover pharma segment growth accelerate third quarter slow first half due number factor include competition key drug remicade concerta upside be expect continue stock company be company hold zack rank buy company report series positive news include promising datum several pivotal study regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication imbruvica settlement humira patent dispute amgen inc amgn free report abbvie also expect several pivotal datum readout regulatory milestone be expect further aid company datum readout pivotal phase iii trinity study rova third line later small cell lung cancer be important catalyst stock moreover fda decision be expect new drug application nda elagolix endometriosis be grant priority review october last year abbvie blockbuster drug humira have be perform well competitive pressure company expect drug performance continue boost topline imbruvica be also do consistently well multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease nordiskshare company increase company carry zack rank company be grant approval expand label diabetes drug victoza include treatment major adverse cardiovascular event adult type ii diabetes august moreover new diabetes drug fiasp receive approval september treat adult diabetes december fda approve ozempic semaglutide once daily pre filled pen improve glycaemic control type ii diabetes patient also receive approval rebinyn hemophilia unite state refixia treatment adolescent adult same indication europe company expect launch ozempic approval same europe certainly boost company revenue moreover company serve almost half insulin market quarter diabetes market grow diabetes market certainly boost topline company share rise company sport zack rank strong buy company have diversify portfolio livestock companion animal product company increase share dermatology product dog market companion animal business have be perform well launch apoquel cytopoint company acquire nexvet biopharma last year boost pipeline solution chronic pain management dog cat company also expand reach poultry diagnostic product major european market zoetis topline be expect benefit cytopoint be launch europe fourth quarter company expect cattle herd size increase drive growth strong product portfolio consistently successful pipeline development anticipate growth demand drug company likely attract investor attention year well zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
296,ZTS,third quarter report cycle be draw close quarterly result have be strong overall beat percentage be line recent quarters growth rate have be particularly impressive also estimate revision trend have be mostly favorable nov member accounting index total market capitalization have report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning big biotech pharma company report week generic maker mylan myl free report miss estimate earning sale due lower epipen sale one report last week pfizer pfe free report allergan agn free report beat earning expectation revenue come line zoetis zts free report beat expectation earning sale pfizer zoetis raise earning guidance allergan increase only upper end earning outlook here have small biotech pharma company be set report third quarter result nov let see thing be shape quarter puma biotechnology inc pbyi free report puma biotech be schedule release earning market close deliver positive surprise last quarter company earning track record have be good so far have deliver average positive surprise last quarters quarter puma have earning esp zack rank hold indicate likely positive surprise zack consensus estimate be peg loss share uncover best stock buy sell re report earning esp filter puma biotechnology only market product nerlynx neratinib be launch treatment positive breast cancer august so be first quarter puma record sale nerlynx read more puma earning surpass estimate again intrexon corporation xon free report intrexon be also schedule announce result market close last quarter company deliver positive earning surprise trail quarters miss expectation twice surpass estimate once meeting same other result average negative surprise company have earning esp zack rank sell zack consensus estimate be peg loss cent share investor focus be expect be intrexon pipeline conference call company be develop several candidate partnership other company read more store intrexon earning season ligand pharmaceutical inc lgnd free report ligand be expect report market close ligand earning history have be mixed bag company surpass estimate last quarters miss same other also deliver trail quarter average positive surprise last quarter company come positive earning surprise company have earning esp zack rank strong buy see complete list today zack rank stock here zack consensus estimate earning be peg cent share expect investor focus remain company update regard partnership major pipeline asset third quarter conference call read more store ligand earning season wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
297,ZTS,be approach tail end third quarter report cycle result have be strong overall accelerate revenue growth have be particularly impressive number company come positive surprise have be significantly higher revenue surprise trend historical average also estimate revision trend have be mostly favorable nov member accounting index total market capitalization have report result accord earning outlook total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue meanwhile earning growth be currently expect be please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning big biotech pharma company report week pfizer pfe free report allergan agn free report beat earning expectation revenue come line zoetis zts free report beat expectation earning sale pfizer zoetis raise earning guidance allergan increase only upper end earning outlook here have biotech pharma company be set report third quarter result nov let see thing be shape quarter mylan myl free report mylan be schedule release earning market open deliver negative earning surprise last quarter mylan earning have be mixed so far company top earning estimate trail quarters miss same other company deliver average negative earning surprise trail quarters quarter mylan have earning esp zack rank buy indicate likely positive surprise zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter newly launch product acquisition meda renaissance topical business be likely aid top line however sale epipen auto injector be anticipate decline current quarter result increase competition impact authorize generic launch read more be beat card mylan earning season horizon pharma public limit company hznp free report horizon pharma be also schedule announce result open bell earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be last quarter company deliver positive earning surprise company have earning esp zack rank sell zack consensus estimate be peg cent share company expect continue double digit net sale growth ravicti meanwhile horizon pharma primary care business be pressure due implementation new commercial model read more horizon pharma earning disappointment store keryx inc kerx free report keryx be expect report market close last quarter company deliver negative earning surprise keryx performance last quarters have be disappointing company report wider expect loss trail quarters average negative surprise company have earning esp zack rank see complete list today zack rank strong buy stock here zack consensus estimate be peg loss cent share apart license fee keryx top line comprise revenue generate only market product auryxia be approve treat patient suffering chronic kidney disease ckd dialysis company believe recent formulary addition major part provider boost aurexia sale read more expect keryx earning season look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
298,ZTS,zoetis inc zts free report third quarter earning cent share increase year year report well operational exclude foreign impact basis beat zack consensus estimate cent year year increase earning be primarily due company focus control cost good expense total revenue rise year year operationally exclude impact currency quarter beat zack consensus estimate look zoetis share price movement show stock have outperformed industry year date basis stock be industry decline quarterly report business geographical operate segment unite state international company have diverse portfolio product livestock companion animal revenue unite state segment be year year sale companion animal product geography be primarily due higher sale dermatology portfolio product launch especially simparica however livestock revenue decline mainly due decrease sale cattle product partially offset higher sale poultry medicated feed additive product revenue international segment grow year year operationally report basis livestock sale be report basis operationally quarter mainly due increase sale fish product norway cattle product brazil argentina australia moreover sale companion animal product grow report well operational basis reflect higher sale simparica apoquel outlook raisedzoetis increase sale earning outlook company expect earning range prior guidance share revenue be expect range expect previously zack consensus estimate earning revenue be peg share respectively other company receive approval suvaxyn eu august boost swine vaccine portfolio july company expand reach poultry diagnostic product major european market zoetis also receive approval japan taiwan simparica oral flea tick medication dog company complete acquisition nexvet biopharma plc quarter nexvet be innovator monoclonal antibody therapy companion animal used manage chronic pain address other therapeutic area takezoetis third quarter result be better expect companion animal business perform impressively higher international sale apoquel simparica increase dermatology sale company be focuse control operate cost expense improve margin third quarter zoetis inc price consensus ep surprise zoetis inc price consensus ep surprise zoetis inc quotezack rank key pickszoetis carry zack rank hold better rank stock pharma sector include inc agen free report myriad genetic inc mygn free report exelixis inc exel free report stock carry zack rank buy see complete list today zack rank strong buy stock here loss estimate remain stable narrow last day company deliver positive earning surprise trail quarters average beat myriad earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share be so far year exelixis earning share estimate remain stable cent increase cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
299,ZTS,florham park nj base zoetis inc zts free report be lead global animal health company focuse discovery development manufacture animal health medicine vaccine focus livestock companion animal company come existence follow pfizer decision spin animal health business zoetis diversify portfolio product livestock companion animal continue drive top line growth company company top line benefit addition product acquire abbott laboratory february pharma november nexvet july well performance apoquel other key brand scenario investor focus remain top bottom line number zoetis track record have be impressive company beating earning estimate consistently fact zoetis earning surpass expectation last quarters average positive surprise currently zoetis have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning line zoetis report earning share cent beating zack consensus estimate cent third quarter revenue beat zoetis post revenue surpass zack consensus estimate key stat company complete acquisition nexvet biopharma plc july develop monoclonal antibody therapy management chronic pain other therapeutic area companion animal acquisition zoetis strengthen monoclonal antibody pipeline august zoetis receive approval swine vaccine suvaxyn europe simparcia be approve japan september zoetis also expand poultry diagnostic product european market quarter outlook upgrade zoetis increase outlook company expect earning range share revenue zack consensus estimate earning be share revenue share price impact share company be inactive pre market trading check back later full zts earning report later zoetis inc price ep surprise zoetis inc price ep surprise zoetis inc quotezack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
300,ZTS,merck kgaa be schedule report second quarter earning result aug merck kgaa share price have increase year date industry gain company report result business sector healthcare life science performance material strong performance life science be catalyst sale growth last few quarters be anticipate continue soon be report quarter however sale healthcare division be disappointing last quarter only cancer drug erbitux register sale growth mar recommendation national institute health care excellence erbitux use combination folfiri folfox first line treatment patient ra wild type metastatic colorectal cancer uk be expect boost sale however competitive pressure price reduction be expect hurt sale infertility drug gonal meanwhile year year weaken euro dollar be expect positively impact total sale company mar company receive approval bavencio treatment metastatic merkel cell carcinoma mmcc follow approval advanced bladder cancer drug bring sale quarter moreover company be develop drug partnership pfizer inc pfe free report several cancer indication subsequent quarter company receive positive opinion committee medicinal product human use chmp bavencio july monotherapy adult mmcc patient expect management shed light plan bavencio earning call merck kgaa apr announce agreement divest biosimilar business fresenius part company strategy focus pipeline innovative medicine deal be expect close second half stock warrant lookhere be couple health care stock want consider model show have right combination element positive zack earning esp zack rank strong buy buy hold post earning beat quarter uncover best stock buy sell re report earning esp filter zoetis inc zts free report have earning esp zack rank company be schedule release result aug see complete list today zack rank stock here clovis oncology inc clvs free report have earning esp zack rank company be schedule release result aug more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
301,ZTS,zoetis inc zts free report be schedule report third quarter result nov market open zoetis performance last quarters have be mixed company surpass expectation thrice meeting same once average positive earning surprise last quarters be let see thing be shape announcement zoetis share price movement year date show stock have outperformed industry stock have moved compare industry decline period likely positive surprise proven model show zoetis be likely beat estimate quarter have right combination key ingredient zack esp earning esp represent difference most accurate estimate zack consensus estimate be favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank zoetis currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate combination zoetis zack rank positive esp make confident earning beat upcoming release conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision factor considerzoetis derive majority revenue diversify product portfolio medicine vaccine used treat protect livestock companion animal company continue strengthen diverse product portfolio lifecycle innovation strong customer relationship access new market technology concurrent second earning call zoetis increase outlook company expect earning range share revenue improve outlook also suggest better result third quarter company companion animal business have be boost further penetration new product key country outside unite state apoquel cytopoint new oral parasiticide simparica be drive growth company receive approval clavamox chewable unite state cytopoint european union april canada march approval strengthen canine dermatology portfolio thus provide boost top line zoetis complete acquisition nexvet biopharma innovator monoclonal antibody therapy companion animal july acquisition be expect strengthen zoetis pipeline solution chronic pain management dog cat represent area high need companion animal health expect management throw more light acquisition strategy zoetis inc price ep surprise zoetis inc price ep surprise zoetis inc quoteother stock warrant lookhere be health care stock also want consider model show too have right combination element post earning beat quarter clovis oncology inc clvs free report have earning esp zack rank company be schedule release result nov see complete list today zack rank stock here inc agen free report have earning esp zack rank company be schedule release third quarter result nov acadium pharmaceutical inc acad free report have earning esp currently carry zack rank company be expect release third quarter result nov zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
302,ZTS,conatus pharmaceutical inc cnat free report be expect report third quarter result nov market close conatus earning history have be disappointing company surpass expectation occasion only miss register line result average negative surprise last quarter company deliver negative surprise conatus share have decrease so far year compare unfavorably industry register increase period let see thing be shape upcoming release factor approve product conatus portfolio moment company be yet generate revenue hence investor focus be company progress emricasan orally active pan caspase protease inhibitor emricasan be currently evaluation various phase iib study treatment chronic liver disease include nash fibrosis initiation encore lf clinical trial be now ongoing emricasan phase iib clinical study include encore program patient fibrosis cirrhosis cause nonalcoholic steatohepatitis nash various patient population fourth encore study polt hcv svr patient august conatus announce completion enrollment encore nf study datum study be expect company also plan soon initiate additional study encore xt emricasan encore program conatus have exclusive option collaboration license agreement novartis ag nvs free report worldwide development emricasan july company announce have receive amount novartis deal become effective amount be likely benefit company third quarter revenue operate expense company particularly research development cost be expect rise due continue investment development emricasan earning whispersour proven model do not conclusively show conatus beat earning quarter be stock need have positive earning esp favorable zack rank strong buy buy hold happen be not case here see zack esp conatus have earning esp represent difference most accurate estimate loss cent zack consensus estimate loss cent uncover best stock buy sell re report earning esp filter zack rank conatus currently carry zack rank increase predictive power esp however company need have positive esp be confident earning surprise thus leave case inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock worth consider model have right combination element beat estimate quarter emergent biosolution inc ebs free report be schedule release result nov company have earning esp zack rank see complete list today zack rank stock here zoetis inc zts free report be schedule release result nov company have earning esp carry zack rank well wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
303,ZTS,perrigo company plc prgo free report be expect report second quarter result open bell aug overall company have average trail quarter positive earning surprise last quarter company deliver positive surprise perrigo company price ep surprise perrigo company price ep surprise perrigo company quoteperrigo share have lose so far year industry witness increase let see thing be shape company quarter factor influence quarterprice erosion change market dynamic perrigo prescription pharmaceutical rx segment be likely continue hurt company performance company continue expect tough drug pricing environment impact segment performance anticipate price erosion approximately rx segment come quarters brand consumer healthcare bch business part consumer health care international chci segment be still be impact unfavorable market dynamic country belgium france germany italy bch segment be project underperform yet be report quarter due lower expect revenue certain high margin product department justice antitrust division have be conduct investigation perrigo seek information latter drug pricing practice company announce search warrant be execute corporate office associate ongoing investigation hence company pricing strategy get affected such probe however perrigo constant focus pursue additional brand otc opportunity market well product acquisition new product launch rx segment be expect boost sale future quarters ongoing restructure initiative operate expense discipline be expect support bottom line earning whispersour proven model do not conclusively show perrigo be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp perrigo be most accurate estimate be peg cent share zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank perrigo zack rank hold increase predictive power esp negative earning esp leave earning surprise prediction inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be other company consider model show have right combination element come earning beat quarter zoetis inc zts free report be schedule release result aug earning esp zack rank see complete list today zack rank stock here tesaro inc tsro free report be schedule release result aug company have earning esp zack rank esperion therapeutic inc espr free report be schedule release result aug company have earning esp zack rank trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
304,ZTS,regeneron pharmaceutical inc regn free report be schedule release second quarter result aug open bell company performance have be mixed so far last report quarters surpass earning estimate occasion miss overall company have record average positive earning surprise regeneron share price movement show stock outperformed zack categorize industry year so far specifically stock have rally period industry gain last quarter regeneron pharma miss earning expectation let see thing be shape quarter factor influence pharma key growth driver eylea be likely continue contribute company top line growth however growth pace drug have slow company expect same be single digit note regeneron pharma have global development agreement bayer ag bayry free report outside eylea product revenue ex eylea sale be record bayer company be work expand eylea label diabetic retinopathy ongoing phase iii study apart eylea investor remain focuse performance pcsk inhibitor praluent sale praluent have fail impress so far jan kevzara sarilumab interleukin il receptor monoclonal antibody be approve canada treatment adult patient moderately severely active rheumatoid arthritis have inadequate response intolerance more biologic biologic disease modify rheumatic drug fda also approve kevzara same indication jun european medicine agency ema also approve drug same indication approval kevzara further boost company portfolio addition company be currently enrolling patient study treatment polyarticular course juvenile idiopathic arthritis company also receive boost fda approve dupixent dupilumab injection treatment adult moderate severe atopic dermatitis ad pricing play key role uptake drug expect company throw more light same second quarter earning call focus be company performance particularly eylea dupixient launch investor be also expect await update company pipeline earning whispersour proven model do not conclusively show regeneron pharma be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank regeneron pharma currently carry zack rank company rank be favorable esp make surprise prediction difficult note caution sell rate stock go earning announcement especially company be see negative estimate revision regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc quotestock warrant lookhere be health care stock want consider instead model show have right combination element post earning beat quarter zoetis inc zts free report have earning esp zack rank company be schedule release result aug see complete list today zack rank stock here intercept pharmaceutical inc icpt free report have earning esp zack rank company be expect release result aug hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
305,ZTS,agio pharmaceutical inc agio free report be expect report second quarter result aug share have surge so far year compare favorably industry increase agio performance have be mixed company miss estimate twice trail quarters surpass same other occasion overall agio have average positive surprise agio pharmaceutical inc price ep surprise agio pharmaceutical inc price ep surprise agio pharmaceutical inc quotelast quarter company deliver positive surprise let see thing be shape quarter factor playas development stage company agio do not have approve product portfolio yet investor be thus expect keep eye pipeline update earning call be worth mention company have several interesting candidate pipeline cancer pipeline comprise idhifa enasidenib ag idh mutant inhibitor ag pan idh mutant inhibitor notably agio be develop enasidenib ag collaboration celgene corporation celg free report bring collaboration revenue idhifa be presently fda review treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation company expect fda give decision aug idhifa be be evaluate several phase dose escalation study evaluate hematological solid tumor cancer idh mutation last month company announce positive efficacy safety datum ongoing phase dose escalation expansion study evaluate idhifa patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation agio celgene intend initiate high risk myelodysplastic syndrome study enasidenib apart idhifa agio be also plan initiate phase iii study ag front line aml patient idh mutation soon company plan explore similar regulatory path ag lead nda submission year earning whispersour proven model do not conclusively show agio be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be be most accurate estimate stand zack consensus estimate stand loss share uncover best stock buy sell re report earning esp filter zack rank agio have zack rank increase predictive power esp however company earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter zoetis inc zts free report be schedule release result aug have earning esp zack rank see complete list today zack rank stock here tesaro inc tsro free report be schedule release result aug company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
306,ZTS,investor be always look stock be poise beat earning season zoetis inc zts free report be such company firm have earning come pretty soon event be shape quite nicely report be zoetis be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface zts report fact most accurate estimate current quarter be currently cent share zts compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate zts give stock zack earning esp head earning season zoetis inc price ep surprise zoetis inc price ep surprise zoetis inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give zts have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead zoetis beat be card upcoming report trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
307,ZTS,expect puma biotechnology inc pbyi free report beat estimate likely report second quarter result aug company earning track record have be mixed so far miss estimate trail quarters meet expectation other company deliver average positive surprise last quarters puma biotechnology inc price ep surprise puma biotechnology inc price ep surprise puma biotechnology inc quotepuma share have significantly outperformed industry year date share company have soar industry record increase last report quarter puma deliver positive surprise let see thing be shape announcement factor playpuma biotechnology lead pipeline candidate neratinib be approve fda treatment positive breast cancer last month fda approval be huge boost company give immense commercial potential target market drug be launch earlier week brand name nerlynx however sale drug be record second quarter nerlynx be also review eu same disease several additional study nerlynx target different type breast cancer patient population be currently underway puma believe nerlynx also be develop treatment other cancer include small cell lung cancer nsclc other tumor type express have mutation june company announce positive result single cohort arm phase ii study evaluate neratinib treat positive metastatic breast cancer have metastasize brain addition several phase ii combination study neratinib treatment breast cancer be ongoing apr puma present encourage additional datum breast cancer study san american association cancer research annual aacr neratinib include interim datum phase ii trial patient positive early stage breast cancer have complete trastuzumab base adjuvant therapy interim phase ii datum nsabp fb trial neratinib kadcyla dm positive mbc finally phase ii datum summit study negative breast cancer patient mutation model proven model show puma be likely beat estimate quarterbecause have right combination key ingredient astock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate loss zack consensus estimate loss stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank puma currently carry zack rank hold increase predictive power esp positive esp further make confident earning surprise caution sell rate stock go earning announcement especially company be see negative estimate revision other stock warrant lookhere be health care stock consider model show have right combination element come earning beat quarter syndax pharmaceutical inc sndx free report be expect release result aug earning esp zack rank see complete list today zack rank stock here arena pharmaceutical inc arna free report be schedule release result aug company have earning esp zack rank zoetis inc zts free report be schedule release result aug have earning esp zack rank more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
308,ZTS,zoetis inc zts free report be schedule report second quarter result aug market open zoetis have consistently surpass earning estimate last quarters average positive surprise last quarter company beat expectation positive earning surprise let see thing be shape announcement zoetis share price movement year date show stock have outperformed industry stock have moved compare industry gain period likely positive surprise proven model show zoetis be likely beat estimate quarter have right combination key ingredient zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be cent zack consensus estimate be peg cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank zoetis currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning estimate combination zack rank positive esp make confident earning beat upcoming release conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision zoetis inc price consensus zoetis inc price consensus zoetis inc quotefactor considerzoetis derive majority revenue diversify product portfolio medicine vaccine used treat protect livestock companion animal company continue strengthen diverse product portfolio lifecycle innovation strong customer relationship access new market technology concurrent first earning call zoetis reiterate outlook company expect earning range revenue share company companion animal business have be perform well late apoquel other product launch continue drive growth company expect witness stronger growth companion animal portfolio drive dermatology portfolio apoquel cytopoint further penetration simparica ongoing uptake new vaccine zoetis expect witness growth livestock business overcome product rationalization impact zoetis announce comprehensive operational efficiency initiative be expect generate cost saving more end zoetis recently acquire nexvet biopharma innovator monoclonal antibody therapy companion animal acquisition be expect strengthen zoetis pipeline solution chronic pain management dog cat represent area high need companion animal health expect management throw more light acquisition strategy stock warrant lookhere be health care stock want consider model show too have right combination element post earning beat quarter tesaro inc tsro free report have earning esp zack rank company be expect release result aug see complete list today zack rank stock here impax laboratory have earning esp zack rank company be expect release second quarter result aug biomarin pharmaceutical bmrn free report have earning esp currently carry zack rank company be expect release second quarter result aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
309,ZTS,endo international plc endp free report be expect report second quarter result aug open bell last quarter company deliver positive earning surprise fact pull positive surprise trail quarters record average positive surprise share endo have decline year date zack classify industry gain let see thing be shape quarter factor influence quarterwe believe continue be challenge year endo generic base business legacy brand pain franchise be expect decline further fact generic base business be significant pressure due intensify consortium pricing pressure additional competitive entrant product discontinuation well discrete factor include destock shift purchase timing owing market condition company expect underlie rate base business price erosion be high single digit exclude impact product discontinuance full year impact prior year competitive event impact expect new competitive event segment be project decline high single low double digit percentage range same year be partially offset growth sterile injectable new launch revenue respectively meanwhile endo brand segment continue be pressure due additional competitive entrant well continuous rise number public policy regulatory action include recent cdc guideline related opioid prescribe divestiture strenda also international revenue be expect decline mid high range reflect divestiture litha well competitive pressure paladin impact foreign exchange somar jul endo announce withdraw opioid pain medication opana oxymorphone hydrochloride extend release market follow fda request june move come wake widespread opioid abuse epidemic consequently company expect incur pre tax impairment charge approximately be report quarter remain net book value drug second quarter earning call investor be expect focus company performance update restructure effort generic product portfolio well manufacturing facility network be expect investor earning whispersour proven model do not conclusively show earning beat endo quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be cent zack consensus estimate be peg lower cent uncover best stock buy sell re report earning esp filter zack rank endo currently carry zack rank sell note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision endo international plc price ep surprise endo international plc price ep surprise endo international plc quotestock considerhere be health care stock want consider model show have right combination element post earning beat quarter tesaro inc tsro free report have earning esp zack rank company be expect release result aug see complete list today zack rank stock here esperion therapeutic inc espr free report have earning esp zack rank company be schedule release result aug zoetis inc zts free report have earning esp zack rank company be expect release result aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
310,ZTS,juno therapeutic inc be expect report second quarter result aug last quarter company deliver negative earning surprise year date juno share have soar industry record increase company poor track record so far show negative surprise last quarters average negative earning surprise last quarters be juno therapeutic inc price ep surprisejuno therapeutic inc price ep surprise juno therapeutic inc quotefactor approve product portfolio juno do not generate product revenue yet thus investor focus primarily be company cash burn pipeline update juno be develop cell base cancer immunotherapy base car high affinity tcr technology be hot therapeutic area huge commercial potential presently company most advanced pipeline candidate include jcar jcar use car cell technology target cd jcar be phase study hodgkin lymphoma nhl phase ii study pediatric young adult acute lymphoblastic leukemia pivotal trial jcar dlbcl diffuse large cell lymphoma be expect start company plan bring jcar market nhl early multiple indication end encourage datum early stage study evalaut jcar patient chronic lymphocytic leukemia cll fail treatment ibrutinib be present dec insight study jcar be be apply development jcar treatment cell malignancy however company face major setback last year related development lead pipeline candidate jcar nov juno announce be discontinue development jcar due toxicity witness phase ii rocket study note time release first quarter result juno have maintain expectation cash burn earning whispersour proven model do not conclusively show juno be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank juno zack rank buy increase predictive power esp earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be other worth consider health care stock have right combination element model post earning beat quarter zoetis inc zts free report be schedule release result aug earning esp zack rank see complete list today zack rank stock here tesaro inc tsro free report be schedule release result aug company have earning esp zack rank esperion therapeutic inc espr free report be expect release result aug company have earning esp zack rank more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
311,ZTS,conatus pharmaceutical inc cnat free report be expect report second quarter result aug last quarter conatus earning be line expectation conatus earning history be mixed bag company surpass expectation occasion miss expectation match estimate result average beat conatus pharmaceutical inc price ep surpriseconatus pharmaceutical inc price ep surprise conatus pharmaceutical inc quoteconatus share have rally so far year compare unfavorably increase register industry period let see thing be shape second quarter result factor approve product conatus portfolio moment company do not generate revenue yet hence investor focus likely be company progress emricasan orally active pan caspase protease inhibitor emricasan orally active pan caspase protease inhibitor be be evaluate various phase iib study treatment chronic liver disease include nash fibrosis ongoing study include encore ph encore nf evaluate emricasan patient compensate early decompensate nash cirrhosis potential improvement fibrosis steatohepatitis respectively datum encore ph study be expect encore nf conatus initiate study encore lf be phase iib trial study emricasan monotherapy patient decompensate nash cirrhosis company also plan soon initiate additional study encore xt emricasan encore program conatus be also conduct phase iib study polt hcv svr evaluate emricasan patient liver fibrosis cirrhosis post liver transplant top line datum study be anticipate next year notably dec conatus sign exclusive option collaboration license agreement novartis ag nvs free report worldwide development emricasan earlier month company announce have receive amount novartis deal become effective however amount not be recognize soon be report quarter only benefit next quarter revenue operate expense company be expect rise particularly research development cost due continue investment development emricasan earning whispersour proven model do not conclusively show conatus beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank conatus currently carry zack rank increase predictive power esp however earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element come earning beat quarter zoetis inc zts free report be schedule release result aug have earning esp zack rank see complete list today zack rank stock here tesaro inc tsro free report be schedule release result aug company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
